{"title": "Amer Zeidan", "author": "Amer Zeidan", "url": "https://www.yalemedicine.org/specialists/amer-zeidan", "hostname": "yalemedicine.org", "description": "Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies. Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan's research and clinical care focus on targeting therapies to a patient's diagnosis and working with their own immune system to counter the malignancies.At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology. His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic.Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books.", "sitename": "Yale Medicine", "date": "2021-07-19", "cleaned_text": "- Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste NP-7New Haven, CT 06511 Biography Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies. Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan's research and clinical care focus on targeting therapies to a patient's diagnosis and working with their own immune system to counter the malignancies. At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology. His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic. Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books. Titles - Associate Professor of Internal Medicine (Hematology) - Director, Early Therapeutics Research, Hematology - Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center - Chair, Protocol Review Committee (PRC) I, Yale Cancer Center - Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center - Director, Hematology Research Seminar Series, Hematology - Member, Executive Committee, Yale Cancer Center - Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center - Interim Chief, Hematologic Malignancies Education & Training - MHSJohns Hopkins University (2014) - FellowshipJohns Hopkins Hospital (2013) - InternshipRochester General Hospital (2010) - MBBSUniversity of Jordan (2001) Languages Spoken - (Arabic) - English Additional Information - Scholar in Clinical Research Award: Leukemia and Lymphoma Society (2018), (2019), (2020), (2021), (2022), (2023) - Cancer Clinical Investigator Team Leadership Award: National Cancer Institute (2018), (2019), (2020) - The Tito Bastianello Young Investigator Award: The 13th Annual International Symposium on Myelodysplastic Syndromes (2015) - Cooper Hematology Young Investigator Award: (2015) - Young Investigator Travel Grant: The Society of Oncologic Malignancy (2015), (2016) - Young Investigator Award: American Society of Clinical Oncology (2013), (2014) - Travel Award: 14th Annual Fellows and the 23rd Mayo Clinic Hematology and Oncology Reviews (2013) - Travel Grant: European Group for Blood and Marrow Transplantation (2013) - Scholarship Award: European Society of Hematology - European Group for Blood and Marrow Transplantation (2012) - Educational Grant: National Comprehensive Cancer Centers Network (2012) - 17th International Congress on Myelodysplastic Syndromes. (2023): Abstract Reviewer - King Hussein Cancer Center Research Conference (2022): Abstract Reviewer - Scientific Research Committee, King Hussein Cancer Center Research Conference (2022): Chair - King Hussein Cancer Center Research Conference (2022 - Present): Scientific Director - Yale ASH Highlights Series (2021): Director - Myelodysplastic Syndromes - Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting (2021): Abstract Reviewer - Myelodysplastic Syndromes - Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting (2021): Moderator - 30th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) (2021 - Present): Session Chair - Advanced Science Workshop on Myeloid Malignancies, Yale University (2019): Chair - 4th Annual Hematologic Malignancies Symposium, Yale University (2019): Co-Chair [An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS](http://www.ncbi.nlm.nih.gov/pubmed/36260702)Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski RF, S, List AF, Kutchroo V, Komrokji RS, Kim agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS Blood Advances 2023, 7: controlled trial](http://www.ncbi.nlm.nih.gov/pubmed/37311468)Platzbecker U, Della Porta D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and trial The Lancet 2023 [PMID: 37311468](https://pubmed.ncbi.nlm.nih.gov/37311468), [Effect of real-world polycythemia vera treated Boselli Hamadeh I, Begley R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated 41: e19080-e19080. [DOI: 10.1200/jco.2023.41.16_suppl.e19080](https://doi.org/10.1200/jco.2023.41.16_suppl.e19080). [Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Kreitz S, Pozharskaya V, Shetty J, Degulys A, Finelli C, Cluzeau T, Della Porta M. Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating double-blind, placebo-controlled study of imetelstat in patients (pts) D, Illmer T, Jonasova A, Belohlavkova P, Sherman L, Berry T, Dougherty S, Shah S, Sun L, Wan Y, Huang F, Komrokji R. IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) myelodysplastic syndromes (LR-MDS) relapsed/refractory [DOI: 10.1200/jco.2023.41.16_suppl.7004](https://doi.org/10.1200/jco.2023.41.16_suppl.7004). [Real-world (RW) patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).](https://doi.org/10.1200/jco.2023.41.16_suppl.7044)Zeidan A, Hernandez Donoso L, Hodzic S, Owusu H, Pathak D, Zhou S, Stein E. Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.](https://doi.org/10.1200/jco.2023.41.16_suppl.tps7079)Zeidan A, Fathi A, Issa G, Erba Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. Journal Of Clinical Oncology 2023, 41: INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies](http://www.ncbi.nlm.nih.gov/pubmed/37290996)Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care in Patients With Advanced Hematologic Malignancies INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies](https://doi.org/10.1016/j.clml.2023.05.002)Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care in Patients With Advanced Hematologic Malignancies Clinical Lymphoma & Leukemia 2023 [DOI: 10.1016/j.clml.2023.05.002](https://doi.org/10.1016/j.clml.2023.05.002). Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome Treatments](http://www.ncbi.nlm.nih.gov/pubmed/37195765)Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms\u2014Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments The Journal Myelodysplastic Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms The Cancer - Bewersdorf J, Xie Zeidan A. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment The Cancer Journal Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome](http://www.ncbi.nlm.nih.gov/pubmed/37166332)Allen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients Bewersdorf J, Zeidan A. What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?](http://www.ncbi.nlm.nih.gov/pubmed/37037494)Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer transplant outcomes: a CIBMTR analysis in 3113AML patients](http://www.ncbi.nlm.nih.gov/pubmed/36949156)Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: and tyrosine kinase inhibitor adherence](http://www.ncbi.nlm.nih.gov/pubmed/36939371)Shallis R, Wang Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine [PMID: 36939371](https://pubmed.ncbi.nlm.nih.gov/36939371), [DOI: 10.1182/bloodadvances.2022009074](https://doi.org/10.1182/bloodadvances.2022009074). [Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs.](http://www.ncbi.nlm.nih.gov/pubmed/36919991)Schukow C, Zeidan A, Loghavi S. Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs. Archives Of Pathology & Laboratory Medicine 2023, 147: 631-633. [PMID: 36919991](https://pubmed.ncbi.nlm.nih.gov/36919991), [DOI: in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)](http://www.ncbi.nlm.nih.gov/pubmed/36934059)Bewersdorf J, Xie Z, Bejar R, Borate S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for Hydroxyurea](http://www.ncbi.nlm.nih.gov/pubmed/35917456)Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS A, Giagounidis A, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Santini V. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS](http://www.ncbi.nlm.nih.gov/pubmed/36805300)Frumm S, Shimony S, Stone R, DeAngelo D, Bewersdorf J, Zeidan A, Stahl M. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS Blood Reviews 2023, 60: Zeidan A. How I treat AML incorporating the updated classifications and guidelines Blood [PMID: 36758209](https://pubmed.ncbi.nlm.nih.gov/36758209), [DOI: as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States](http://www.ncbi.nlm.nih.gov/pubmed/36732419)Zeidan A, Pollyea D, Borate U, Vasconcelos M, Bonifacio G, Chen C. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States Annals Of Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia Expert Review [DOI: 10.1080/17474086.2023.2174521](https://doi.org/10.1080/17474086.2023.2174521). [Consensus proposal for revised Working Group response criteria for higher risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36724453)Zeidan A, Platzbecker U, Bewersdorf J, Stahl M, Ad\u00e8s Borate U, Bowen D, Buckstein R, Brunner A, H, N, Witte DeZern Efficace Garcia-Manero Garcia G, Scheinberg P, Stauder R, Van de Loosdrecht A, Wei A, Sekeres M, Fenaux P. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes Norsworthy K, Garcia J, de Claro R, Theoret M, Jen E, Ehrlich L, Zeidan A, Komrokji R. Considerations for Drug Development in Myelodysplastic Research patterns and real-world effectiveness rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.](http://www.ncbi.nlm.nih.gov/pubmed/36655436)Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: analysis. Haematologica MDS Fenaux Buckstein R, Santini V, D\u00edez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji R, Zeidan A, Garcia-Manero G. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in A. Advances in myelodysplastic syndromes: promising novel agents and combination strategies Expert 2023, 16: A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, J, Giuseppi AC, Kreitz S, Pozharskaya Keeperman S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and randomised controlled trial. Lancet. 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874-7. Online ahead of print. PMID: 37311468 - Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With With Advanced L, G, Chen C. Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05327-x. Online ahead of print. PMID: 37341779 - Gurnari C, Xie Z, Zeidan A. How I Manage Transplant Ineligible Patients with Myelodysplastic intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/36493798)Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/36437356)Zeidan A, Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes myelodysplastic syndrome with excess blasts should be approached as a single entity](http://www.ncbi.nlm.nih.gov/pubmed/36397669)Shallis R, Daver N, Altman J, Hasserjian R, Kantarjian H, Platzbecker U, Santini V, Wei A, D, Zeidan A. TP53altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity Cancer 2022, 129: 175-180. a response criterion in myelodysplastic syndromes (MDS)](http://www.ncbi.nlm.nih.gov/pubmed/36379923)Brunner A, Gavralidis A, Ali N, Hunter A, Komrokji R, Zeidan A, Sallman D. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2022-158465)Bewersdorf J, Patel Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients (HMA) Failure](https://doi.org/10.1182/blood-2022-158626)Bewersdorf J, Shallis R, Sharon E, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A Multi-Center Ib Trial of Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Lymphoma (MCL): A Population-Based Analysis](https://doi.org/10.1182/blood-2022-164959)Di M, Long Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Neoplasms Treated with Ruxolitinib](https://doi.org/10.1182/blood-2022-165156)Stempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical (AML) V, Shallis R, Thompson E, Lopes de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B, Zeidan A. Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic (HR-MDS)](https://doi.org/10.1182/blood-2022-158592)Bewersdorf V, Shallis R, Thompson E, Lopes de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B, Zeidan A. Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) Responses with Luspatercept in the Study](https://doi.org/10.1182/blood-2022-157486)Platzbecker U, Santini V, Komrokji D, Pozharskaya V, Ha X, Nadal J, Fenaux P. Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept Blood 2022, 140: 9808-9810. [DOI: 10.1182/blood-2022-157486](https://doi.org/10.1182/blood-2022-157486). [Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study](https://doi.org/10.1182/blood-2022-157487)Platzbecker A, Garcia-Manero V, Ha X, Nadal J, Miteva D, Fenaux P. Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from [Overall Survival and Progression-Free Following Luspatercept Treatment in the MEDALIST Trial](https://doi.org/10.1182/blood-2022-157489)Santini V, Fenaux P, Zeidan A, Komrokji R, Buckstein X, Miteva D, Yucel A, Nadal J, Platzbecker U. Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial Blood 2022, 140: 4079-4081. [DOI: 10.1182/blood-2022-157489](https://doi.org/10.1182/blood-2022-157489). [Treatment Patterns Initiating Oral Decitabine and Cedazuridine a Real-World Setting](https://doi.org/10.1182/blood-2022-157926)Zeidan A, Divino V, DeKoven M, Wang E, Chen J, Salimi T, Epstein R. Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or with Sabatolimab Added to Hypomethylating Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2022-158612)Zeidan A, Ando K, Rauzy O, Turgut M, Cairoli R, Hou H, Kwong Y, Arnan Sangerman M, Meers Pullarkat F, J, Marques Ramos P, Fenaux P, Miyazaki Primary Results of Stimulus-MDS1: Randomized, Placebo-Controlled Phase II Study with Sabatolimab Added to Hypomethylating (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis](https://doi.org/10.1182/blood-2022-158622)Bewersdorf J, Grimshaw A, Platzbecker U, Fenaux P, Sekeres M, Zeidan A, Stahl M. International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Blood 2022, 140: 9811-9812. [DOI: 10.1182/blood-2022-158622](https://doi.org/10.1182/blood-2022-158622). [Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2022-160002)Zeidan A, Cheng W, Kamalakar R, Miller C, Bui C, Montez M, Yee T, Wu Z, Huntington S. Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia Blood 2022, 140: 3282-3283. Adult U, Fenaux Giagounidis A, Y, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Marques Ramos P, Zeidan A. Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-M) in Adult mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis](https://doi.org/10.1182/blood-2022-166692)Zeidan A, Gautam S, Yu R, Lan Z, Grinblatt D, ElSouda D, Spalding J, Block A, Touya M, Pandya B. Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)](https://doi.org/10.1182/blood-2022-167259)Zeidan A, DeZern A, Borate U, Kobata K, Ide S, Sabo J, Marques Ramos P, Sun H, Lyons R, Garcia-Manero G. Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents](https://doi.org/10.1182/blood-2022-167360)Zeidan A, Tsai S, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents Blood 2022, 140: 10847-10848. [DOI: 10.1182/blood-2022-167360](https://doi.org/10.1182/blood-2022-167360). [Imetelstat Achieved Prolonged, Continuous Heavily Transfused Non-Del(5q) Lower-Risk Study](https://doi.org/10.1182/blood-2022-169050)Platzbecker Komrokji V, Van Eygen K, Raza A, Germing U, Berry T, Dougherty S, Shah S, Sun L, Huang F, Feller F, Wan Y, Ikin A, Sherman L. Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk [DOI: 10.1182/blood-2022-169050](https://doi.org/10.1182/blood-2022-169050). [How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform](https://doi.org/10.1182/blood-2022-170376)Moseley A, Freidlin B, Shallis Zeidan Little R, Erba H, Leblanc M, Othus M. How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within Platform Blood 2022, 140: 8932-8933. [DOI: 10.1182/blood-2022-170376](https://doi.org/10.1182/blood-2022-170376). [Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)](https://doi.org/10.1182/blood-2022-157326)Liu H, Sharon E, Karrison T, Zha Y, Fulton N, Streicher H, Sweet K, Yaghmour G, Liu J, Jonas B, Schimmer A, Grant S, Zeidan A, Hildebrandt G, Hourigan C, Lowrey C, Mattison R, Palmisiano N, Salhotra A, Tzachanis D, Baer M, Lin T, Patel P, Chen H, Stadler W, Odenike O, Larson R, Gajewski T, Stock W. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy Baseline Transfusion Status](https://doi.org/10.1182/blood-2022-157666)Zeidan A, Ng C, Yellow-Duke A, Lamarre N, Cheng W, Ma E. Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By 10.1182/blood-2022-157666](https://doi.org/10.1182/blood-2022-157666). [Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2022-158276)Zeidan A, Mosher K, Souza S, Mirakhur B, Keer H, Taylor J. Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias](https://doi.org/10.1182/blood-2022-162367)Xie Z, Smith A, Komrokji R, Al Ali N, Patel A, Saygin C, Zeidan A, Bewersdorf J, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Foran J, Badar T, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg J, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Chandhok N, Soong D, Taylor J, Brunner A, Carraway H, Singh A, Geyer S, Padron E, Patnaik M, Savona M, Al-Kali A. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Treated in the Ascertain Trial (ASTX727-02)](https://doi.org/10.1182/blood-2022-163841)Savona M, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg J, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Oganesian A, Chan W, Hao Y, Azab M, Garcia-Manero G. Survival in Bi-Allelic TP53 TP53 mut) MDS Subjects Treated Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program](https://doi.org/10.1182/blood-2022-169074)Zeidan A, Fradette C, Rozova A, Toiber Temin N, Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program Blood 140: Trials Network Precision Medicine Initiative](https://doi.org/10.1182/blood-2022-169307)Little R, Othus M, Assouline S, Ansher S, Atallah E, Lindsley R, Freidlin B, Gore S, Harris L, Hourigan C, Ivy S, Jiwani S, Langan E, Luger D, Perales M, Radich J, Ramineni B, Salk J, Stiff P, Stock W, Stone R, Uy G, Williams P, Wood B, Worthington K, Yee L, Zeidan A, Zhang J, Litzow M, Erba H. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network 2022, 9057-9060. patients with relapsed or refractory syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36309981)Zeidan AM, Borate O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng W, Zhou Y, Hoffman D, Harb JG, Potluri J, GarciaManero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu Odenike Carraway H, Fenaux P, Nazha A, Komrokji R, S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in coming of age](http://www.ncbi.nlm.nih.gov/pubmed/36357283)Xie Z, Chen E, Stahl M, Zeidan A. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk entity with unique unmet Loghavi S, acute myeloid leukemia: a distinct genetic entity with unique unmet CIBMTR analysis in 3113 AML patients](http://www.ncbi.nlm.nih.gov/pubmed/36310182)Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Impact of pre-transplant induction and consolidation cycles on allogeneic transplant myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36287540)Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36266326)Zeidan AM, Bewersdorf CS, DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML).](http://www.ncbi.nlm.nih.gov/pubmed/36163756)Stahl M, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Bewersdorf JP. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma, Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML).](http://www.ncbi.nlm.nih.gov/pubmed/36163849)Zeidan AM, Westermann J, Kovacsovics T, Assouline Schuh AC, Kim HJ, Macias GR, Sanford D, Luskin MR, Stein EM, Malek K, Lyu J, Stegert M, Esteve J. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid Leukemia (ND AML). Clinical The DA, Santini V, Sanz GF, Sekeres MA, AH, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. The Myelodysplastic Syndromes Studies Clinical Trial Program. Clinical Lymphoma, Myeloma Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups.](http://www.ncbi.nlm.nih.gov/pubmed/36163976)Alrawabdeh J, Alzu'bi M, Hamadneh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma, Myeloma Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/s2152-2650(22)00747-9)Zeidan A, Westermann J, Kovacsovics T, Assouline Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2152-2650(22)00761-3)Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups](https://doi.org/10.1016/s2152-2650(22)00945-4)Alrawabdeh J, Alzu'bi M, Hamadneh MDS-529 The Prognostic Value of the Endothelial Activation and Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups Clinical The Program](https://doi.org/10.1016/s2152-2650(22)00947-8)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma The Myelodysplastic Syndromes Studies on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2152-2650(22)01214-9)Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/s2152-2650(22)01303-9)Zeidan A, Westermann J, Kovacsovics T, Assouline Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid The Program](https://doi.org/10.1016/s2152-2650(22)01420-3)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. The Myelodysplastic Syndromes Studies Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups](https://doi.org/10.1016/s2152-2650(22)01428-8)Alrawabdeh J, Alzu'bi M, Hamadneh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups Clinical medicine and immunomodulatory drugs: a focus on higher-risk disease](http://www.ncbi.nlm.nih.gov/pubmed/36045390)Mohty R, A, Brissot Zeidan A, Mohty M. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease patients with acute myeloid leukemia previously treated with venetoclax](http://www.ncbi.nlm.nih.gov/pubmed/36108424)Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated requires a evaluation](http://www.ncbi.nlm.nih.gov/pubmed/35984499)Stempel JM, Podoltsev NA, Zeidan AM, Lee AI, Shallis RM. Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires CHIPing away the progression potential of CHIP: A new reality in the making 101001. decitabine in patients with AML ineligible for intensive chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/35507690)Zeidan AM, Fenaux P, Gobbi Thomas X, JP, Keer H, Hao Y, Azab M, D\u00f6hner H. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible Buckstein RJ, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/35734924)Komrokji RS, Carraway HE, Germing dose escalation and randomized trial of BI 836858 in patients with rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.](https://doi.org/10.1200/jco.2022.40.16_suppl.7554)Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, S, Podoltsev N, Zeidan A, Shallis R. Body mass index and venetoclax-hypomethylating agent induction therapy for acute AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000845168.01159.c0)Zeidan A, Pollyea D, Borate G, T, C. P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS care regimens in older patients with late-stage IDH2 Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Zeidan A, Chen C, Lord-Bessen J, Yu P, Shi L, Guo S, Bluemmert I, Yu X, Hasan M, Martin Regueira P, De Botton S. Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage IDH2 relapsed or with lower-risk myelodysplastic syndromes (LR-MDS) R, Miteva D, Keeperman K, Holot N, Zhang J, Hughes C, Rosettani B, Yucel A, Platzbecker U. Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from 40: 7056-7056. Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng W, Bui C, Svensson A. P766: CLINICAL OUTCOMES IN PATIENTS THE MYELODYSPLASTIC SYNDROMES IN PROGRAM](https://doi.org/10.1097/01.hs9.0000846032.37876.c9)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. THE MYELODYSPLASTIC SYNDROMES 6: 682-683. [DOI: STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000845216.33320.a2)Zeidan A, Westermann J, Kovacsovics T, Assouline S, Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS 6: 481-482. IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431607)Zeidan A, Divino V, DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) J, Rosettani B, Yucel A, Platzbecker U. P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35729009)Zeidan AM, Tsai JH, Karimi J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35488900)Sekeres MA, Schuster Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35614009)Zeidan AM, Joshi N, Kale H, Wang WJ, S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Beach C, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig D, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Azacitidine and Durvalumab in First-line Treatment of Elderly Patients Therapy for Higher-Risk Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/34972214)Zeidan AM, Boss I, Beach C, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A Randomized Phase 2 Trial of acute myeloid leukemia.](http://www.ncbi.nlm.nih.gov/pubmed/35298594)Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with MDS/AML resistant to targeted inhibitors of mutant IDH1/2](http://www.ncbi.nlm.nih.gov/pubmed/35273342)Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, PARP inhibition in IDH1/2 mutant MDS/AML of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia](https://doi.org/10.1016/s2666-6367(22)00329-3)Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev R, Perrault S, M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Therapy 2022, 28: s139-s140. [DOI: [A Phase Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies](http://www.ncbi.nlm.nih.gov/pubmed/35260349)Zeidan AM, Cook RJ, Bordoni R, Berenson S, Zhou G, Asatiani E, Srinivas N, Savona MR. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies Patients with Acute Promyelocytic Leukemia in the United States](http://www.ncbi.nlm.nih.gov/pubmed/34724703)Bewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/34981142)Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute Zeidan and syndromes. In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (Cancer Principles and Practice of Oncology). Twelfth Edition. Wolters Kluwer. 2022. [The Current Understanding Treatment Paradigm Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia](https://doi.org/10.3390/hemato2040051)Shallis R, Stahl M, Bewersdorf J, Zeidan A. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Patel Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid Ilhan O, Sekeres MA, Zeidan AM, JT, in lower-risk myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial](http://www.ncbi.nlm.nih.gov/pubmed/34749571)Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ. salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial Leukemia Acute Leukemia](https://doi.org/10.1182/blood-2021-144992)Bewersdorf J, Goshua G, Patel K, Shallis R, S, Zeidan A. Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to 2021, 138: 113-113. [DOI: 10.1182/blood-2021-144992](https://doi.org/10.1182/blood-2021-144992). [Evaluation of International Working Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Frontline Setting](https://doi.org/10.1182/blood-2021-146331)Bewersdorf J, Wei W, Jaiani A, Patel P, Mehta R, Neparidze N, Shallis R, Podoltsev N, Brunner A, Zeidan A. Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with 10.1182/blood-2021-146331](https://doi.org/10.1182/blood-2021-146331). [Survival Kinase A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2021-151066)Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary \"Real World\" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States Blood 2021, 138: 282-282. [DOI: 10.1182/blood-2021-151066](https://doi.org/10.1182/blood-2021-151066). [Characteristics and Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study](https://doi.org/10.1182/blood-2021-146254)Xie Z, Hyun M, Komrokji R, Zeidan A, Madanat Y, Zeidner J, Coombs C, Griffiths E, Lai C, Kishtagari A, Foran J, Badar T, Arana Yi C, Desai P, Ades L, Osman A, Taylor J, Deeg H, Brunner A, Carraway H, Al Ali N, Bewersdorf J, Prebet T, Singh A, Tsai C, Chandhok N, Soong D, Patnaik M, Savona M, Al-Kali A. Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large 2021, 138: Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2021-151988)Ball S, Jain A, Aguirre L, Al Ali N, Bewersdorf J, Hayden A, Siddon A, Lykon J, Madarang E, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Swoboda D, Pollyea D, Zeidan A, Komrokji R. Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia Blood 2021, 138: 2331-2331. [DOI: to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)](https://doi.org/10.1182/blood-2021-145015)Zeidan A, Roopcharan K, Radich J, Bewersdorf J, Bhatt V, Sharon E, Little R, Gore S, Caldwell A, Luger S, Litzow M. Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Longer-Term Follow-up of from the Ascertain Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611)Garcia-Manero McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Savona M. Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of PMC8701611](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611), to Hypomethylating Agent Use](https://doi.org/10.1182/blood-2021-144852)Zeidan A, Divino DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes Onvansertib, in Combination Leukemia Erlander M, Ruffner K, Wang E. Predictive Biomarkers Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination Syndromes (HR-MDS): The MDS Studies in Program](https://doi.org/10.1182/blood-2021-145626)Zeidan A, Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Bengoudifa B, Sachs J, Garcia-Manero G. Sabatolimab (MBG453) Higher-Risk Syndromes (HR-MDS): The MDS Studies in 138: 4669-4669. [DOI: 10.1182/blood-2021-145626](https://doi.org/10.1182/blood-2021-145626). Syndrome](https://doi.org/10.1182/blood-2021-145646)Zeidan A, Borate U, Pollyea Garcia J, Filshie R, Odenike O, Watson A, Krishnadasan R, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Kye S, Garcia-Manero G. Venetoclax and Azacitidine in the Treatment of 2021, of Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Komrokji R, Zeidan A, Garcia-Manero G, Buckstein R, Rose S, Fabre S, Miteva D, Zhang J, Yucel A, Hughes C, Fenaux P. Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes Thompson E, Lopes de Menezes D, Rose S, Boss I, Fox B. Immune and Epigenetic Landscape of TP53- mutated Acute Clonal Cytopenias of Significance Z, Campestri G, Lasho T, Finke C, Li M, Binder M, Robertson K, Fernandez J, Hyun M, Komrokji R, Zeidan A, Bewersdorf J, Zeidner J, Coombs C, Madanat Y, Griffiths E, Lai C, Savona M, Shah M, Litzow M, Tefferi A, Mangaonkar A, N, Al-Kali A, Patnaik M. Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Lower-Intensity in Randomized, Phase 3 IDHentify Trial](https://doi.org/10.1182/blood-2021-147593)DiNardo C, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Zeidan A, Bluemmert I, Yu X, Hasan M, Martin-Regueira P, de Botton S. Outcomes for Patients Other Lower-Intensity Therapies in Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible Intensive Chemotherapy (IC)](https://doi.org/10.1182/blood-2021-147601)DiNardo C, Dohner H, Zeidan A, Schuh A, Vyas P, Stein E, Wei A, de Botton S, Chen C, Lord-Bessen J, Martin-Regueira P, Lersch F, Gong J, Guo S, Shi L, Montesinos P. Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not [DOI: 10.1182/blood-2021-147601](https://doi.org/10.1182/blood-2021-147601). As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States](https://doi.org/10.1182/blood-2021-147926)Zeidan A, Pollyea D, Borate U, Vasconcelos G, Chen C. Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States Blood 2021, 138: 277-277. [DOI: 10.1182/blood-2021-147926](https://doi.org/10.1182/blood-2021-147926). [Evaluating Complete Remission with a Response Criterion in Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2021-151815)Brunner A, Gavralidis A, Al Ali N, Komrokji R, Zeidan A, Sallman D. Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Subgroup from the Ascertain Phase 3 Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701430)Savona M, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Garcia-Manero G. Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain mutant-IDH2 myeloid leukaemia (AG221-AML-005): a trial](http://www.ncbi.nlm.nih.gov/pubmed/34672961)DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, D\u00f6hner H. Enasidenib plus azacitidine versus azacitidine alone in patients newly mutant-IDH2 myeloid leukaemia (AG221-AML-005): a single-arm, phase Treatment](http://www.ncbi.nlm.nih.gov/pubmed/34674983)Zeidan AM, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, Hill K, Joshi N. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Myelodysplastic (MDS)](https://doi.org/10.1016/s2152-2650(21)01452-x)Zeidan I, Sabo J, Purkayastha D, Ramos P, Sun H, Lyons R, Garcia-Manero G. Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Myelodysplastic (MDS)](https://doi.org/10.1016/s2152-2650(21)01808-5)Zeidan I, Sabo J, Purkayastha D, Ramos P, Sun H, Lyons R, Garcia-Manero G. MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES](https://doi.org/10.1016/j.leukres.2021.106681.52)Zeidan A, Garcia J, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, Zhou Y, Naqvi K, Kye S, Manero G. P53 Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE](https://doi.org/10.1016/j.leukres.2021.106681.10)Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES Lu W, Shallis R, Winer with myelofibrosis: A systematic review and meta-analysis.](https://doi.org/10.1200/jco.2021.39.15_suppl.7045)Bewersdorf J, Sheth A, Vetsa Grimshaw R, Tallman M, R, Zeidan A, Stahl M. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis. for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.](https://doi.org/10.1200/jco.2021.39.15_suppl.6587)Dhakal P, Lyden E, Gundabolu K, Zeidan A, Loh K, Fisher A, Bhatt V. Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) higher-risk myelodysplastic syndromes.](https://doi.org/10.1200/jco.2021.39.15_suppl.7043)Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors agent discontinuation with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes.](https://doi.org/10.1200/jco.2021.39.15_suppl.tps7054)Zeidan A, Garcia J, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, Zhou Y, Naqvi K, Kye S, Garcia-Manero G. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk imetelstat in transfusion-dependent subjects with IPSS low or M, Savona M, Madanat Y, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Rizo A, Berry T, Feller F, Santini V. IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or syndromes that are S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus Journal Of Buccisano F, Sallman D, Mazzucato M, Madden L, Martini M, Van Breda E, Dolcetti R, Busca A, Cook G, Onida F, Versari A, Kiladjian J, Walter R, Garderet L, Robin M, Signore A. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2 Hemato 2021, 2: 79-88. [DOI: 10.3390/hemato2010004](https://doi.org/10.3390/hemato2010004). - Sharma A, Martin Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study E. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato 2021, 2, 79-88. - Rory M. Shallis,Maximilian Stahl, Jan Philipp Bewersdorf and Amer M. Zeidan. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia](http://www.ncbi.nlm.nih.gov/pubmed/32998961)Zeidan AM, Ridinger M, Lin TL, Becker Schiller Patel PA, Spira AI, Tsai ML, Samu\u00eblsz E, Silberman SL, Erlander M, Wang ES. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Clinical Cancer Zeidan AM. A complex karyotype and a genetic mutation in acute myeloid leukaemia Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Prozora Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia Patients with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2020-139468)Wang R, Shallis R, Bewersdorf J, Zeidan A, Huntington X, Podoltsev N. Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 10.1182/blood-2020-139468](https://doi.org/10.1182/blood-2020-139468). [Contemporary Practice Patterns of Use Among Older Patients with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2020-139531)Shallis R, Wang R, Bewersdorf J, Zeidan A, Huntington S, Davidoff A, Ma X, Podoltsev N. Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 44-45. [DOI: 10.1182/blood-2020-139531](https://doi.org/10.1182/blood-2020-139531). - Davidoff Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2020-139668)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia of PD-1 to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy](https://doi.org/10.1182/blood-2020-139752)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy Blood 2020, 136: 11-12. [DOI: 10.1182/blood-2020-139752](https://doi.org/10.1182/blood-2020-139752). [Clinical Efficacy and Safety 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330281)Savona E, Yee K, Al-Kali A, Zeidan A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Garcia-Manero G. Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) in Patients (Pts) with Higher-Risk or Acute Myeloid Kim Y, Platzbecker U, Schuh A, Sekeres M, Westermann J, Xiao Z, Malek K, Scott J, Niolat J, Peyrard S, Ma F, Kiertsman F, Stegert M, Hertle S, Fenaux P, Santini V. The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial](https://doi.org/10.1182/blood-2020-136184)Pandya B, Qi C, Yang H, Garnham A, Shah M, Zeidan A. Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial Blood 2020, 136: 7-7. [DOI: 10.1182/blood-2020-136184](https://doi.org/10.1182/blood-2020-136184). [Streamline - FLT3 -Mutated Acute Myeloid A, Gilligan A, Gautam S, Grinblatt D, Elsouda D, Sullivan L, Pandya B. Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Blood 2020, 136: 30-31. [DOI: 10.1182/blood-2020-136366](https://doi.org/10.1182/blood-2020-136366). [Molecular Characterization of Clinical Response and in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine](https://doi.org/10.1182/blood-2020-136922)Daigle S, Choe S, DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, De Botton S, Stone R, Frattini M, Franovic A, Xu E, Winkler T, Wu B, Vyas P. Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated Blood 2020, AML Previously Treated with FLT3 inhibitors](https://doi.org/10.1182/blood-2020-137251)Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf J, Barth D, Zeidan A, Yilmaz M, Dinner S, Deutsch Y, Frankfurt O, Litzow M, Al-Kali A, Foran J, Sproat L, Jovanovic B, Daver N, Perl A, Altman J. Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)](https://doi.org/10.1182/blood-2020-137734)Zeidan A, Wang V, Radich J, Bewersdorf J, Bhatt V, Sharon E, Gore S, Luger S, Litzow M. Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) Blood 2020, 136: 1-1. [DOI: 10.1182/blood-2020-137734](https://doi.org/10.1182/blood-2020-137734). [Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study](https://doi.org/10.1182/blood-2020-140564)Goksu S, Khatib J, Bacik Goksu B, Wang R, Patel P, Vusirkala M, Cole S, Seyhanli A, Ozer M, Collins R, Chung S, Zeidan A, Madanat Y. Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study Blood 2020, 136: 2-3. and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis](https://doi.org/10.1182/blood-2020-136671)Bewersdorf J, Tallman M, Cho C, Zeidan A, Stahl M. Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis Blood 2020, 136: 34-35. [DOI: 10.1182/blood-2020-136671](https://doi.org/10.1182/blood-2020-136671). [The Direct Medical Costs of Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents](https://doi.org/10.1182/blood-2020-139642)Joshi N, Kale H, Corman S, Hill K, Wert T, Zeidan A. The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents Blood [DOI: 10.1182/blood-2020-139642](https://doi.org/10.1182/blood-2020-139642). [Efficacy Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Analysis from the Medalist Study](https://doi.org/10.1182/blood-2020-137232)Komrokji R, Platzbecker U, Fenaux P, Garcia-Manero M, Zeidan A, DeZern A, Savona M, Shetty J, Ito R, Zhang G, Ha X, Sinsimer D, Backstrom J, Verma A. Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Blood 2020, 136: 13-15. [DOI: 10.1182/blood-2020-137232](https://doi.org/10.1182/blood-2020-137232). [Feasibility of Peri-Transfusion Quality with Myelodysplastic Syndromes](https://doi.org/10.1182/blood-2020-139919)Abel G, Klepin H, Magnavita R, Winer E, Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with for Newly Diagnosed Acute Myeloid Leukemia](http://www.ncbi.nlm.nih.gov/pubmed/33119479)DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, D\u00f6hner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia Journal of volasertib in combination with decitabine in patients with acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/32951163)Cortes J, Podoltsev N, Kantarjian H, Borthakur M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia International Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Glasdegib + Azacitidine](https://doi.org/10.1016/s2152-2650(20)30732-1)Wang E, Bell T, Zeidan A, Bhattcharyya H, Kudla A, Chan G, Sekeres M. AML-205: Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study](https://doi.org/10.1016/s2152-2650(20)30973-3)Zeidan A, Garcia-Manero G, DeZern A, Fenaux P, Greenberg A, Mufti G, Buckstein V, Laadem A, Zhang J, Rampersad A, Sinsimer D, Louis C, Linde P, Platzbecker U, Sekeres M. MDS-179: Clinical in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study Clinical Lymphoma Myeloma & Leukemia 2020, Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the 3 MEDALIST Trial](https://doi.org/10.1016/s2152-2650(20)30971-x)Fenaux P, Santini V, Mufti G, Diez-Campelo A, Ad\u00e8s L, Verma A, Savona M, Laadem A, Ito R, Zhang J, Rampersad A, Sinsimer D, Morison J, Louis C, Linde U. MDS-171: Effects Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial Clinical Lymphoma Myeloma & Leukemia 2020, 20: s317. [DOI: 10.1016/s2152-2650(20)30971-x](https://doi.org/10.1016/s2152-2650(20)30971-x). [AML-187: STIMULUS Clinical Trial Program: Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Leukemia](https://doi.org/10.1016/s2152-2650(20)30727-8)Zeidan H, Miyazaki Y, Platzbecker U, Schuh A, Westermann J, Malek K, Scott J, Niolat J, Peyrard S, Kiertsman F, Stegert M, Fenaux P. AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the 3 MEDALIST Trial](https://doi.org/10.1016/s2152-2650(20)30972-1)Platzbecker U, Fenaux P, Mufti G, Garcia-Manero A, Ad\u00e8s L, Verma A, Savona M, Laadem A, Ito R, Zhang J, Rampersad A, Morison J, Louis C, Linde P, Santini V. MDS-175: Assessment of Dose-Dependent with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial Clinical Lymphoma & Leukemia 2020, 20: s318. [DOI: 10.1016/s2152-2650(20)30972-1](https://doi.org/10.1016/s2152-2650(20)30972-1). [MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence](https://doi.org/10.1016/s2152-2650(20)30733-3)Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence Clinical Lymphoma Myeloma & Leukemia 2020, [DOI: 10.1007/978-3-030-51878-3_7](https://doi.org/10.1007/978-3-030-51878-3_7). [Special considerations in the of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts](http://www.ncbi.nlm.nih.gov/pubmed/32563283)Zeidan AM, Boddu PC, Patnaik MM, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts The receiving hypomethylating agents: a large population-based study in the United States](http://www.ncbi.nlm.nih.gov/pubmed/32433746)Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States a Medicare insured patient population: Role of initial care setting and socioeconomic status.](https://doi.org/10.1200/jco.2020.38.15_suppl.e19057)Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. [DOI: 10.1200/jco.2020.38.15_suppl.e19057](https://doi.org/10.1200/jco.2020.38.15_suppl.e19057). [Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed leukemia (ND-AML).](https://doi.org/10.1200/jco.2020.38.15_suppl.7501)Dinardo C, Schuh A, Stein E, Montesinos P, Wei A, De Botton S, Zeidan A, Fathi A, Quek L, Kantarjian H, Frattini M, Lersch F, Gong J, Franovic A, Vyas P, Dohner H. Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed 2020, 38: 7501-7501. [DOI: 10.1200/jco.2020.38.15_suppl.7501](https://doi.org/10.1200/jco.2020.38.15_suppl.7501). [Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).](https://doi.org/10.1200/jco.2020.38.15_suppl.7518)Komrokji R, Sekeres M, Zeidan Fenaux P, List Dezern A, Greenberg P, Savona M, Jurcic J, Verma A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts 7518-7518. [DOI: 10.1200/jco.2020.38.15_suppl.7518](https://doi.org/10.1200/jco.2020.38.15_suppl.7518). [Glasdegib in combination untreated higher-risk myelodysplastic syndromes acute myeloid leukemia (AML) and chronic leukemia (CMML): Effects on marrow recovery and transfusion independence.](https://doi.org/10.1200/jco.2020.38.15_suppl.7526)Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. Journal Of Clinical Oncology 2020, 38: 7526-7526. [DOI: 10.1200/jco.2020.38.15_suppl.7526](https://doi.org/10.1200/jco.2020.38.15_suppl.7526). [Health-related syndromes E, Bell Zeidan Bhattacharyya H, Kudla A, Chan G, Sekeres M. Health-related quality of life (HRQoL) in patients higher-risk syndromes receiving glasdegib [DOI: with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.](https://doi.org/10.1200/jco.2020.38.15_suppl.7554)Zeidan A, Garcia-Manero G, Dezern A, Fenaux P, Greenberg A, Mufti G, Buckstein V, Laadem A, Zhang J, Rampersad A, Sinsimer D, Louis C, Linde P, List A, Sekeres M. Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. Journal Of Clinical Oncology 2020, 38: 7554-7554. [DOI: 10.1200/jco.2020.38.15_suppl.7554](https://doi.org/10.1200/jco.2020.38.15_suppl.7554). [Patterns of outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States](http://www.ncbi.nlm.nih.gov/pubmed/32311013)Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study](http://www.ncbi.nlm.nih.gov/pubmed/32132655)Stahl M, Shallis RM, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Acu\u00f1a-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/32100599)Shallis RM, Stahl M, Wei W, Montesinos P, Lengline Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Acu\u00f1a-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy Leukemia use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey](http://www.ncbi.nlm.nih.gov/pubmed/32026740)Pine SM, Stone PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based L, Verma A, Savona A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji AF. Luspatercept in Patients with Lower-Risk Myelodysplastic [DOI: 10.1056/nejmoa1908892](https://doi.org/10.1056/nejmoa1908892). [Hypomethylating agent and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study](http://www.ncbi.nlm.nih.gov/pubmed/31878809)Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched (AML) or Myelodysplastic J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes [Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?](https://doi.org/10.1182/blood-2019-127277)Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. [DOI: 10.1182/blood-2019-127277](https://doi.org/10.1182/blood-2019-127277). Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Impact the for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia](https://doi.org/10.1182/blood-2019-127563)Podoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Phlebotomy and Hydroxyurea Use in Patients Agents Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)](https://doi.org/10.1182/blood-2019-128821)Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US) Blood 2019, 134: 4748-4748. [DOI: 10.1182/blood-2019-128821](https://doi.org/10.1182/blood-2019-128821). [Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study](https://doi.org/10.1182/blood-2019-126643)Zeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Study Blood 2019, 134: 116-116. [DOI: 10.1182/blood-2019-126643](https://doi.org/10.1182/blood-2019-126643). [Clinical Outcomes of Older Patients Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States](https://doi.org/10.1182/blood-2019-127398)Zeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in United States Blood 2019, 134: 646-646. [DOI: 10.1182/blood-2019-127398](https://doi.org/10.1182/blood-2019-127398). [Incidence and Risk Factors of Second Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea](https://doi.org/10.1182/blood-2019-127568)Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia](https://doi.org/10.1182/blood-2019-131520)Strickland S, Podoltsev N, Mohan S, Zeidan A, Childress M, Ayers G, Byrne M, Gore S, Stuart R, Savona M. The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Blood 134: 180-180. Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study](https://doi.org/10.1182/blood-2019-123535)Zeidan A, Gilligan A, Gautam S, Hu N, Grinblatt D, Pandya B. Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study Blood 2019, 134: 5082-5082. [DOI: 10.1182/blood-2019-123535](https://doi.org/10.1182/blood-2019-123535). [Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (FLT3mut+) Qi C, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) of Gilteritinib Versus Salvage the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2019-123819)Zeidan A, Qi Pandya B, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2019-124034)Zeidan Schuster Krauter J, Maertens J, Gyan E, Joris M, Menne T, Vyas P, Ma W, O'Connell A, Zeremski M, Kudla A, Chan G, Sekeres M. Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients Modulator, in a Phase I Dose-Escalation Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)](https://doi.org/10.1182/blood-2019-124291)Fan J, Wang H, Couto S, Yao T, Uy G, Zeidan A, Minden M, Montesinos P, DeAngelo D, Altman J, Koprivnikar J, Vyas P, Y, Bel\u00e9n Vidriales M, Gjertsen B, Buchholz T, Pourdehnad CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Relapsed or Refractory Acute of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute DeAngelo D, Palmer J, Seet C, Tallman M, Wei X, Li Y, Hock N, Burgess M, Hege K, Stock W. A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1](https://doi.org/10.1182/blood-2019-127041)Zeidan A, Miyazaki Y, Platzbecker U, F, Fenaux P. A Randomized, Double-Blind, Placebo-Controlled, II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1 Blood with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Study](https://doi.org/10.1182/blood-2019-122896)Zeidan A, Cavenagh J, Voso M, Taussig D, Tormo M, Boss I, Copeland W, Gray V, Previtali A, O'Connor T, Rose S, Beach C, Silverman L. Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Study Blood 2019, 134: 829-829. [DOI: 10.1182/blood-2019-122896](https://doi.org/10.1182/blood-2019-122896). [Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine](https://doi.org/10.1182/blood-2019-122980)Garcia-Manero Griffiths E, Yee K, Zeidan A, Al-Kali A, Dao K, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Shastri A, DeZern A, O'Connell C, Roboz G, Oganesian A, Hao Y, Keer H, Azab M, Savona M. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) 10.1182/blood-2019-122980](https://doi.org/10.1182/blood-2019-122980). [Assessment of Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2019-123064)Fenaux P, Mufti G, Buckstein R, Santini R, List A, Zeidan A, Verma A, Laadem A, Ito R, Zhang J, Rampersad A, Sinsimer D, Linde P, Garcia-Manero G, Platzbecker U. Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood 2019, 134: 841-841. with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study](https://doi.org/10.1182/blood-2019-123966)Uy G, Minden M, Montesinos P, DeAngelo D, Altman J, Koprivnikar J, Vyas P, Y, Vidriales M, Gjertsen B, Esteve J, Buchholz T, Couto S, Fan J, Hanna B, Li L, Pierce D, Hege K, Pourdehnad M, Zeidan A. Clinical with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a 2019, 134: 232-232. [DOI: 10.1182/blood-2019-123966](https://doi.org/10.1182/blood-2019-123966). Study of in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Joris Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Zeidan A. A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid 177-177. [DOI: 10.1182/blood-2019-124050](https://doi.org/10.1182/blood-2019-124050). [A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome](https://doi.org/10.1182/blood-2019-124994)Zeidan A, Pollyea Garcia Borate U, Odenike O, Bajel A, Watson A, G\u00f6tze K, Nolte F, Tan P, Hong W, Dunbar M, Zhou Y, Gressick L, Ainsworth W, Harb J, Salem A, Hayslip J, Swords R, Garcia-Manero G. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Myelodysplastic Syndrome 565-565. [DOI: Onvansertib (ONV), Decitabine Patients Acute Myeloid Leukemia (R/R AML)](https://doi.org/10.1182/blood-2019-126262)Zeidan A, Schiller G, Lin T, Becker P, Patel P, Wang E, Spira A, Tsai M, Ridinger M, Croucher P, Erlander M, Silberman S. Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), Decitabine Patients (pts) Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim II Results from an Ongoing, Randomized Study](https://doi.org/10.1182/blood-2019-130362)DiNardo C, Schuh A, Stein E, Fernandez P, Wei A, De Botton S, Zeidan A, Fathi A, Quek L, Kantarjian H, Frattini M, Lersch F, Gong J, Franovic A, MacBeth K, Vyas P, D\u00f6hner H. Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from Randomized Study Blood 2019, 134: 643-643. [DOI: 10.1182/blood-2019-130362](https://doi.org/10.1182/blood-2019-130362). [Association of provider experience and in patients with myelodysplastic syndromes receiving hypomethylating agents](http://www.ncbi.nlm.nih.gov/pubmed/31570040)Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating with relapsed/refractory acute myeloid leukaemia in phase Ib](https://doi.org/10.1093/annonc/mdz251.001)Zeidan A, Becker P, Patel P, Schiller G, Tsai M, Lin T, Wang E, Erlander M, Cortes J. 1066O Polo-like with relapsed/refractory acute Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/j.clml.2019.07.090)DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Wang X, Gong J, Kapsalis S, Hickman D, Zhang V, Winkler T, Daigle S, Vyas P. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Acute Myeloid Leukemia (ND [Underutilization guidelinerecommended supportive care among older adults with multiple myeloma in the United States](http://www.ncbi.nlm.nih.gov/pubmed/31381151)Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guidelinerecommended supportive care among older adults with multiple myeloma in the United States the combination with patients with relapsed or refractory acute myeloid leukemia](https://doi.org/10.1158/1538-7445.sabcs18-ct102)Zeidan A, Becker P, Spira A, Patel P, Schiller G, Tsai M, Lin T, Ridinger M, Erlander M, Silberman S, Cortes J. Abstract CT102: Phase Ib safety, preliminary anti-leukemic activity and the combination with decitabine in patients with relapsed the combination with patients with relapsed or refractory acute myeloid leukemia](https://doi.org/10.1158/1538-7445.am2019-ct102)Zeidan A, Becker P, Spira A, Patel P, Schiller G, Tsai M, Lin T, Ridinger M, Erlander M, Silberman S, Cortes J. Abstract CT102: Phase Ib safety, preliminary anti-leukemic activity and the combination with decitabine in patients with relapsed or refractory myeloid leukemia Cancer Research 2019, 79: ct102-ct102. [DOI: 10.1158/1538-7445.am2019-ct102](https://doi.org/10.1158/1538-7445.am2019-ct102). - Zeidan A, Boddu P. Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? The Hematologist 2019, 16 [DOI: 10.1182/hem.v16.4.9711](https://doi.org/10.1182/hem.v16.4.9711). [RBC transfusion independence MDS patients receiving hypomethylating agents: a population-level analysis](http://www.ncbi.nlm.nih.gov/pubmed/31170846)Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000562388.60660.bc)DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, Botton S, Kantarjian H, Stone R, Lam D, Wang X, Gong J, Kapsalis S, Hickman D, Zhang V, Winkler T, Wu B, Vyas P. PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE LEUKEMIA HemaSphere 2019, 3: 460-461. [DOI: 10.1097/01.hs9.0000562388.60660.bc](https://doi.org/10.1097/01.hs9.0000562388.60660.bc). - Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of newly diagnosed acute myeloid leukemia (ND AML).](https://doi.org/10.1200/jco.2019.37.15_suppl.7011)Dinardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Gong J, Zhang V, Winkler T, Wu B, Vyas P. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with newly diagnosed acute myeloid leukemia (ND Shallis RM, Wang R, Davidoff Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges 70-87. [PMID: 31101526](https://pubmed.ncbi.nlm.nih.gov/31101526), [DOI: 10.1016/j.blre.2019.04.005](https://doi.org/10.1016/j.blre.2019.04.005). [Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?](http://www.ncbi.nlm.nih.gov/pubmed/30861094)Vandsemb EN, Kim TK, Zeidan AM. Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.](http://www.ncbi.nlm.nih.gov/pubmed/30865915)Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. [PMID: the Modern Era: A Single Center Experience](https://doi.org/10.1016/j.bbmt.2018.12.796)Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. [DOI: 10.1016/j.bbmt.2018.12.796](https://doi.org/10.1016/j.bbmt.2018.12.796). - Boddu P, Zeidan AM. Myeloid disorders after autoimmune disease Best Practice & hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/30636526)Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes Cham. https://doi.org/10.1007/978-3-030-51878-3_7. 2020. Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis](https://doi.org/10.1182/blood-2018-99-111052)Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Blood 2018, 132: 370-370. [DOI: 10.1182/blood-2018-99-111052](https://doi.org/10.1182/blood-2018-99-111052). [Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort](https://doi.org/10.1182/blood-2018-99-112495)Stahl M, Wei W, Montesinos P, Lengline E, Shallis Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Rabinovich E, Yoo B, Podoltsev N, Gore S, Zeidan A. Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort Blood 2018, 132: 1428-1428. [DOI: 10.1182/blood-2018-99-112495](https://doi.org/10.1182/blood-2018-99-112495). [Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort](https://doi.org/10.1182/blood-2018-99-112974)Stahl M, Wei W, Montesinos P, Lengline E, Shallis Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Rabinovich E, Yoo B, Podoltsev N, Gore S, Zeidan A. Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort Blood 2018, 132: 4040-4040. [DOI: 10.1182/blood-2018-99-112974](https://doi.org/10.1182/blood-2018-99-112974). [Association between Oncologist Ownership and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility](https://doi.org/10.1182/blood-2018-99-115140)Huntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility Blood 2018, (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2018-99-116497)Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions Blood 2018, 132: 838-838. [DOI: 10.1182/blood-2018-99-116497](https://doi.org/10.1182/blood-2018-99-116497). [Use of Statins, Survival and Incidence Among Older Adults with Essential Thrombocythemia: A Population-Based Study](https://doi.org/10.1182/blood-2018-99-119118)Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based 2018, 132: 4865-4865. of Statins, Survival Older Adults with Polycythemia Vera: A Population-Based Study](https://doi.org/10.1182/blood-2018-99-119272)Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: with Newly-Diagnosed Acute Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database](https://doi.org/10.1182/blood-2018-99-119755)Shallis R, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt V, Sekeres Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Podoltsev N, Gore S, Zeidan A. Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database Blood 2018, 132: 3999-3999. [DOI: 10.1182/blood-2018-99-119755](https://doi.org/10.1182/blood-2018-99-119755). [Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States](https://doi.org/10.1182/blood-2018-99-119791)Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States Blood 2018, 132: 978-978. [DOI: 10.1182/blood-2018-99-119791](https://doi.org/10.1182/blood-2018-99-119791). [Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey](https://doi.org/10.1182/blood-2018-99-113888)Pine Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a 1825-1825. [DOI: 10.1182/blood-2018-99-113888](https://doi.org/10.1182/blood-2018-99-113888). Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2018-99-110805)Fenaux P, Platzbecker U, Mufti G, Garcia-Manero J, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern A, Jurcic J, Germing P, Hellstr\u00f6m-Lindberg E, Zeidan A, Laadem A, Benzohra A, Zhang J, Rampersad A, Linde P, Sherman M, Komrokji R, List A. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood 2018, 132: in Patients with (R/R) Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2018-99-112590)Zeidan A, Schiller G, Spira Patel P, Tsai M, Ridinger M, Silberman S, Erlander M, Cortes J. Preliminary Safety, in Patients with Relapsed Timed Sequential Therapy (TST) for Knaus L, Ghiaur G, Showel M, DeZern A, Pratz K, Smith B, Levis M, Foster M, Coombs C, Streicher H, Karp J, Luznik L, Gojo I. Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/30413901)Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic on survival and risk of thrombosis among older patients with polycythemia vera](http://www.ncbi.nlm.nih.gov/pubmed/30333100)Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera anemia: Etiology, molecular pathogenesis, and is a prerequisite to taming it](http://www.ncbi.nlm.nih.gov/pubmed/30314642)Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it Blood Reviews 2018, 34: 1-15. [PMID: 30314642](https://pubmed.ncbi.nlm.nih.gov/30314642), [DOI: 10.1016/j.blre.2018.09.001](https://doi.org/10.1016/j.blre.2018.09.001). - Huntington W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma therapy in search of the right place](http://www.ncbi.nlm.nih.gov/pubmed/30024293)Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place Expert Review Of Hematology 2018, 11: 715-726. case series of Jehovah's Witnesses with myeloid malignancies](http://www.ncbi.nlm.nih.gov/pubmed/30088044)Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah's Witnesses with Syndromes following Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating MDS: clinical outcomes and their predictors in a large international patient cohort](http://www.ncbi.nlm.nih.gov/pubmed/30037803)Stahl M, DeVeaux M, de Witte A, Maciejewski Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort Blood Advances study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/30027436)Kim TK, DeVeaux M, Stahl M, Perreault Isufi Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation The genetic and molecular pathogenesis of myelodysplastic Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/29963936)Stahl M, DeVeaux M, Montesinos N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute azacitidine therapy: are we using realistic estimates?](http://www.ncbi.nlm.nih.gov/pubmed/29891916)Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute Clinical 2018, 36: e22124-e22124. 10.1200/jco.2018.36.15_suppl.e22124](https://doi.org/10.1200/jco.2018.36.15_suppl.e22124). - Stahl M, Zeidan Inhibition in Myelofibrosis\u2014The Long of iron chelation therapy on overall survival in sickle cell disease and thalassemia: A systematic review](http://www.ncbi.nlm.nih.gov/pubmed/29635754)Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and thalassemia: A systematic review American Journal AML: outcomes and their predictors in a large international patient cohort](http://www.ncbi.nlm.nih.gov/pubmed/29685952)Stahl M, DeVeaux M, Montesinos P, Itzykson Serrano J, Gore AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Blood Advances 923-932. [PMID: 29685952](https://pubmed.ncbi.nlm.nih.gov/29685952), acute myeloid leukemia: a large U.S. web-based M, Pine JE, Litzow DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study](http://www.ncbi.nlm.nih.gov/pubmed/29649620)Stahl M, DeVeaux Montesinos P, Itzykson R, Ritchie N, Verma V, Kobbe G, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Transplantation And Cellular Therapy 2018, 24: 1754-1758. [PMID: 29649620](https://pubmed.ncbi.nlm.nih.gov/29649620), [DOI: 10.1016/j.bbmt.2018.03.025](https://doi.org/10.1016/j.bbmt.2018.03.025). Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia Journal Of to chelate in MDS: AM. Lenalidomide in non-deletion 5q lower-risk a quarter [More less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/29435332)Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with in Myelofibrosis-The Long Road Ahead. JAMA oncology, Epub ahead of Print. 2018 Mar 8. doi: 10.1001/jamaoncol.2017.5802. - Natalie Uy, Michelle Nadeau, Maximilian Stahl, and Amer M. Zeidan. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic J Blood Med. 2018 10.2147/JBM.S136575. eCollection 2018. Review. PMID: 29713210 [Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/29259002)Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States](https://doi.org/10.1182/blood.v130.suppl_1.675.675)Giri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) 675-675. [DOI: 10.1182/blood.v130.suppl_1.675.675](https://doi.org/10.1182/blood.v130.suppl_1.675.675). [A Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies](https://doi.org/10.1182/blood.v130.suppl_1.640.640)Zeidan A, Cook R, Bordoni R, Asatiani E, Zhou G, Faivre T, Byrne M, Savona M. A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Hematologic Malignancies changing landscape or a AM. Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing localized breast cancer: A population-based study](http://www.ncbi.nlm.nih.gov/pubmed/28902882)Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box](http://www.ncbi.nlm.nih.gov/pubmed/28787256)Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life Journal Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/28758974)Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment with higherrisk myelodysplastic syndromes in firstline MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higherrisk myelodysplastic [DOI: M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are lymphoma after autologous stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/28640385)Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Costeffectiveness analysis of consolidation with brentuximab vedotin for highrisk Hodgkin survival in older patients with chronic myelomonocytic leukemia in the United States: A large populationbased study](http://www.ncbi.nlm.nih.gov/pubmed/28621841)Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.](https://doi.org/10.1200/jco.2017.35.15_suppl.7057)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A Of Clinical Oncology 2017, 7057-7057. [DOI: 10.1200/jco.2017.35.15_suppl.7057](https://doi.org/10.1200/jco.2017.35.15_suppl.7057). - Huntington Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma Zeidner J, Blackford A, Rizzieri D, Frattini M, Levy M, Schroeder M, Ferguson A, Sheldon K, Dezern A, Gojo I, Gore S, Streicher H, Luznik L, Duffield A, Smith B. A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes Management of myelofibrosis: JAK inhibition and Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study](https://doi.org/10.1016/s0145-2126(17)30234-5)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Agent in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study](https://doi.org/10.1016/s0145-2126(17)30145-5)Zeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large 55: Phase Zeidner J, Blackford A, Duffield A, Rizzieri D, Frattini M, Levy M, Schroeder M, Ferguson A, Sheldon K, Dezern A, Gojo I, Gore S, Streicher H, Luznik L, Smith B. 64 A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and in a patient with advanced myelodysplastic syndrome](http://www.ncbi.nlm.nih.gov/pubmed/28220192)Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced mechanisms and clinical applications](http://www.ncbi.nlm.nih.gov/pubmed/28192601)Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium](http://www.ncbi.nlm.nih.gov/pubmed/28111463)Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?](http://www.ncbi.nlm.nih.gov/pubmed/28094843)Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end Cancer Gore, and Amer Methqal Zeidan. An Illustrated Guide to Diagnosis and Treatment. In Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment. Edited by Ashkan Emadi, MD, PhD, Judith E. Karp, MD. Springer. 2017. - Vu H. Duong and Amer Methqal Zeidan. An Illustrated Guide to Diagnosis and Treatment. In Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment. Edited by Ashkan Emadi, MD, PhD, Judith E. Karp, MD. Springer. 2017. - Wang A, Brunet CM, Zeidan AM. Barta SK, Bejar R, Bennett JM, Castro Deeg DeZern Frankfurt Head D, Horsfall Komrokji LA, BL, Walker AR, Westervelt P, DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2016, with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort](https://doi.org/10.1182/blood.v128.22.1063.1063)Stahl M, Podoltsev N, DeVeaux M, Perreault S, Itzykson V, U, Montesinos Fern\u00e1ndez P, Zelterman D, Kim T, Prebet T, Gore S, Zeidan A. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort Blood 2016, 128: 1063-1063. [DOI: 10.1182/blood.v128.22.1063.1063](https://doi.org/10.1182/blood.v128.22.1063.1063). [Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study](https://doi.org/10.1182/blood.v128.22.394.394)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study Blood 2016, 128: [Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue](https://doi.org/10.1182/blood.v128.22.1188.1188)Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue Blood 2016, 128: 1188-1188. [DOI: 10.1182/blood.v128.22.1188.1188](https://doi.org/10.1182/blood.v128.22.1188.1188). [Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)](https://doi.org/10.1182/blood.v128.22.2820.2820)Zeidner J, Montiel-Esparza R, Knaus H, Berglund S, Zeidan A, McCurdy S, Prince G, Gondek L, Ghiaur G, Showel M, DeZern A, Pratz K, Smith B, Levis M, Foster M, Jamieson K, Van Deventer H, Streicher H, Karp J, Luznik L, Gojo I. Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and Myelodysplastic Bone marrow failure disease scientific symposium 2016](http://www.ncbi.nlm.nih.gov/pubmed/27923195)Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016 Leukemia blood product transfusion practices among providers who care for patients with acute leukemia in the United States](http://www.ncbi.nlm.nih.gov/pubmed/27878822)Pine AB, Lee E, Sekeres M, Steensma Luger S, Stone R, Erba HP, GarciaManero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States Transfusion Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate with relapsed/refractory Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities World Journal Of Stem on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*](http://www.ncbi.nlm.nih.gov/pubmed/27774847)DeZern AE, Zeidan AM, Barnard J, Hand W, Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS of erythroblast Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/27650975)Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States](http://www.ncbi.nlm.nih.gov/pubmed/27558206)Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States Leukemia & 58: 982-985. Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes Expert Opinion On Emerging Drugs 2016, 21: 283-300. DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated Medicareenrolled patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/26970288)Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Diseaserelated costs of care and survival among Medicareenrolled patients syndromes: Findings from a large national database](http://www.ncbi.nlm.nih.gov/pubmed/26914833)Fletcher SA, Cronin AM, Odejide OO, Gore AJ, Steensma DP, Abel GA. Intensity of endoflife care for patients with myelodysplastic syndromes: Findings from a large national database Cancer 2016, [PMID: 26914833](https://pubmed.ncbi.nlm.nih.gov/26914833), [DOI: Rheumatologic Manifestations of Hematologic Malignancies. Current Rheumatology Reviews. 2016 Aug 15. [Epub ahead print]. [The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.](http://www.ncbi.nlm.nih.gov/pubmed/26008639)Hamoudeh E, Zeidan AM, Barbarotta L, Rosano N. The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. Current Reviews 2016, 12: 231-9. Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)](https://doi.org/10.1182/blood.v126.23.3285.3285)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed Leukemia: Results of a North American Web-Based Survey](https://doi.org/10.1182/blood.v126.23.4455.4455)Lee E, Smith B, Merrey J, Lee A, Podoltsev N, Barbarotta L, Litzow M, Prebet T, Luger S, A. Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey Blood 2015, 126: 4455-4455. [DOI: 10.1182/blood.v126.23.4455.4455](https://doi.org/10.1182/blood.v126.23.4455.4455). [North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia](https://doi.org/10.1182/blood.v126.23.1138.1138)Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia Blood 2015, 126: 1138-1138. [DOI: 10.1182/blood.v126.23.1138.1138](https://doi.org/10.1182/blood.v126.23.1138.1138). [Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)](https://doi.org/10.1182/blood.v126.23.873.873)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United [DOI: 10.1182/blood.v126.23.873.873](https://doi.org/10.1182/blood.v126.23.873.873). [Myelodysplastic Syndromes and Acute after Radiotherapy, a Population-Based Study](https://doi.org/10.1182/blood.v126.23.3295.3295)Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Cancer after Radiotherapy: A Population-Based Study](https://doi.org/10.1182/blood.v126.23.1676.1676)Zeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: Population-Based Study Blood 2015, 126: Care from a Large National Database](https://doi.org/10.1182/blood.v126.23.3287.3287)Fletcher S, Cronin A, Zeidan A, Odejide O, Gore S, Davidoff A, Steensma D, Abel G. Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database Checkpoint Inhibitor Ipilimumab: A Phase I Trial](https://doi.org/10.1182/blood.v126.23.1666.1666)Zeidan A, Zeidner J, Duffield A, Knaus H, Ferguson A, Sheldon K, DeZern A, Gojo I, Gore S, Streicher H, Luznik L, of Myelodysplastic Syndromes (MDS) Following Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: I Trial Blood 2015, 126: 1666-1666. 10.1182/blood.v126.23.1666.1666](https://doi.org/10.1182/blood.v126.23.1666.1666). [Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)](https://doi.org/10.1182/blood.v126.23.2889.2889)DeZern A, Zeidan A, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz G, Komrokji R, Garcia-Manero G, Steensma D, Sekeres M. Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research (MDS CRC) Blood 2015, 126: 2889-2889. [DOI: 10.1182/blood.v126.23.2889.2889](https://doi.org/10.1182/blood.v126.23.2889.2889). [Results Phase 2 Trial Lenalidomide Monotherapy in Patients with Relapsed/Refractory Smith B, Carraway H, Gojo I, Sakoian S, Gore S, DeZern A. Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory clinical evaluating real-life effectiveness of exisiting therapies](https://doi.org/10.2217/ijh.15.25)Zeidan A. Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies International Journal Of Hematologic Oncology 4: 215-217. [DOI: 10.2217/ijh.15.25](https://doi.org/10.2217/ijh.15.25). [Azacitidine for the of therapyrelated myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study](http://www.ncbi.nlm.nih.gov/pubmed/26577691)Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD, intergroup T. Azacitidine with or without Entinostat for the treatment of therapyrelated myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study British Journal Hensen M, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment Expert patients with lowerrisk myelodysplastic syndromes: Is one model better?](http://www.ncbi.nlm.nih.gov/pubmed/26284571)Zeidan AM, Sekeres X, Ali N, GarciaManero G, Steensma DP, Roboz G, Barnard A, Maciejewski JP, List AF, Komrokji RS, Consortium O. Comparing the prognostic value of risk stratifying models for patients with lowerrisk myelodysplastic syndromes: Is one of patients with higher-risk myelodysplastic syndromes treated Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine](http://www.ncbi.nlm.nih.gov/pubmed/26440749)Zeidan AM, Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine Clinical Lymphoma patients with myelodysplastic syndromes (MDS)](https://doi.org/10.1016/j.clml.2015.07.094)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes N, Zeidan AM. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes Expert Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?](http://www.ncbi.nlm.nih.gov/pubmed/26260295)Zeidan AM, Sekeres Al Ali N, Garcia-Manero Steensma Roboz G, JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one North American Web-Based Survey](http://www.ncbi.nlm.nih.gov/pubmed/26363982)Lee EJ, Smith Merrey T, Luger AM. of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey Clinical OR, Subtil A. Leukaemic [DOI: 10.1016/s0140-6736(15)61165-5](https://doi.org/10.1016/s0140-6736(15)61165-5). [Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/26274794)Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes Journal Of Comparative Effectiveness Patients with LowerRisk Myelodysplastic Syndromes: Is one model better?](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751065)Zeidan A, Sekeres M, Wang X, Ali N, GarciaManero G, Steensma D, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski J, List A, Komrokji R. Comparing the Prognostic Value of Risk stratifying Models for Patients with LowerRisk Myelodysplastic Syndromes: Is one Oncologist: Will the Progress Fulfill the Promise?](http://www.ncbi.nlm.nih.gov/pubmed/26194858)Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress MDS: Recent developments and future directions](http://www.ncbi.nlm.nih.gov/pubmed/26119927)Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future Blood Reviews 30: 1-10. [PMID: 26119927](https://pubmed.ncbi.nlm.nih.gov/26119927), Epigenetic Therapy in Acute Myeloid Leukemia: Current and A POPULATION-BASED STUDY](https://doi.org/10.1016/s0145-2126(15)30081-3)Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A Research BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM](https://doi.org/10.1016/s0145-2126(15)30321-0)Komrokii R, Zeidan A, Ali N, Padron E, Lancet J, Steensma D, Dezern A, Roboz G, Jabbour E, Sekeres M, RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM Leukemia Research 2015, 39: s158-s159. [DOI: 10.1016/s0145-2126(15)30321-0](https://doi.org/10.1016/s0145-2126(15)30321-0). [44 DISEASE-SPECIFIC COSTS PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)](https://doi.org/10.1016/s0145-2126(15)30045-x)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. 44 DISEASE-SPECIFIC COSTS OF CARE AND SURVIVAL AMONG MEDICARE-ENROLLED PATIENTS WITH response](http://www.ncbi.nlm.nih.gov/pubmed/25869077)Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25874142)Khan M, Wasim A, Mirrakhimov AE, McMahon BA, Judge DP, Chu LC, Banavali A, Zeidan AM. Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer Case Reports In Oncological Komrokji RS. Current state of prognostication and risk stratification in benefit Baer MR, Stuart BC, Shenolikar RA, Gore SD. Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D Parker, Oscar Colegio, Antonio Subtil. Leukaemic vasculitis from myelodysplastic syndrome. Lancet Journal. 2015 AM, Pronovost PJ, Haut ER. Eliminating Health Care Disparities With Mandatory Clinical Decision Support Medical Care the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)](https://doi.org/10.1182/blood.v124.21.1935.1935)Zeidan A, Sekeres M, Garcia-Manero G, Barnard J, Al Ali N, Zimmerman C, Roboz G, Steensma D, DeZern A, Jabbour E, Kantarjian H, Zell K, Wang Q, Gore S, Nazha A, Maciejewski J, List A, Komrokji R. The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated A, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes Journal Of Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy](http://www.ncbi.nlm.nih.gov/pubmed/25499624)Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy Clinical Lymphoma Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives Expert and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies](http://www.ncbi.nlm.nih.gov/pubmed/25072931)Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS](http://www.ncbi.nlm.nih.gov/pubmed/24995683)Zeidan AM, Lee J, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS British hypomethylating agents failure in patients with myelodysplastic Zeidan A. An update on type 2B von Willebrand disease [DOI: 10.1586/17474086.2014.868771](https://doi.org/10.1586/17474086.2014.868771). - Amer M Zeidan Steven D. Gore. New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral Chemotherapy-Free Upfront Management. Clinical Cancer Research Journal. 2014 Oct 1;20(19):4985-93. - Amer and Amy DeZern. Spontaneous Splenic rupture during induction therapy for acute myeloid leukemia. Leukemia and Lymphoma. 2014 Jan;55(1):209-12. - Mikhail S, Zeidan A. Stem cells in gastrointestinal cancers: The road less travelled. World Journal Of Related HLA-Haploidentical Bone Marrow Transplantation](http://www.ncbi.nlm.nih.gov/pubmed/24296490)Zeidan AM, Forde Symons H, Chen Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation Transplantation Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study](https://doi.org/10.1182/blood.v122.21.2777.2777)Prebet T, Sun Z, Ketterling R, Greenberg P, Zeidan A, Litzow M, Gabrilove J, Erba H, Paietta E, Czader M, Gore S, Tallman M. Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Intergroup Study Blood 2013, 122: 10.1182/blood.v122.21.2777.2777](https://doi.org/10.1182/blood.v122.21.2777.2777). [Validation Of a Brief Arsenic Trioxide Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival](https://doi.org/10.1182/blood.v122.21.3963.3963)Leech M, Stewart M, Zhang X, Bashey A, Holland H, Solomon S, Carraway H, Smith B, Morris L, Gore S, Zeidan A. Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival Blood 2013, 122: 3963-3963. [DOI: 10.1182/blood.v122.21.3963.3963](https://doi.org/10.1182/blood.v122.21.3963.3963). [The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)](https://doi.org/10.1182/blood.v122.21.2771.2771)Zeidan A, Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) After Related T-Cell Posttransplantation Cyclophosphamide (PTCy)](https://doi.org/10.1182/blood.v122.21.4629.4629)Zeidan A, Forde P, Symons H, Chen A, Smith B, Fuchs E, Luznik L, Jones R, Bola\u00f1os-Meade J. The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell an international web-based survey of healthcare providers](http://www.ncbi.nlm.nih.gov/pubmed/24092259)Zeidan AM, Wellman Forde J, Streiff thromboembolism stem cell transplantation patients: an international web-based survey of healthcare providers Journal Boikos S, Bose S, Lipsett P, D, King KE, Gerber J, DeZern A. Spontaneous splenic rupture during induction chemotherapy for acute prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza).](https://doi.org/10.1200/jco.2013.31.15_suppl.7126)Zeidan A, Sun Z, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza). Journal Of Clinical Oncology 2013, 31: 7126-7126. [DOI: 10.1200/jco.2013.31.15_suppl.7126](https://doi.org/10.1200/jco.2013.31.15_suppl.7126). [Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).](https://doi.org/10.1200/jco.2013.31.15_suppl.e17584)Gore S, Davidoff Hendrick F, Duong V, Stuart B, Baer M, Shenolikar R, Zeidan A. Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload 2013, 31: e17584-e17584. [DOI: 10.1200/jco.2013.31.15_suppl.e17584](https://doi.org/10.1200/jco.2013.31.15_suppl.e17584). - Zeidan A, Myelodysplastic Syndrome 2013, 189-210. [DOI: 10.1007/978-3-642-36229-3_12](https://doi.org/10.1007/978-3-642-36229-3_12). [P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine](https://doi.org/10.1016/s0145-2126(13)70172-3)Zeidan A, Zhuoxin S, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine Leukemia Research 2013, 37: s79-s80. [DOI: 10.1016/s0145-2126(13)70172-3](https://doi.org/10.1016/s0145-2126(13)70172-3). [P-181 Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes](https://doi.org/10.1016/s0145-2126(13)70229-7)Zeidan A, Davidoff A, Hendrick F, Duong V, Stuart B, Baer M, Gore S. P-181 Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes Leukemia Research 2013, 37: performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes](https://doi.org/10.1016/s0145-2126(13)70207-8)Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. P-159 Lenalidomide performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes Leukemia Research 2013, 37: azacitidine-lenalidomide Zeidan, Steven Gore, Rami Komrokji - Iron Chelation for Myelodysplastic Syndromes-associated Iron Overload: Where Do we Stand?Mhairi Mitchell, Steven Gore, and Amer Zeidan - Myelodysplastic Syndromes: Jocelyn Wozney, Karen Krok, and Javier Bola\u00f1os-Meade. Successful Treatment of severe refractory hepatic graft versus host disease by cadaveric liver transplantation. Leukemia and Lymphoma. 2013 Dec;54(12):2756-9. - What lies within - Novel Strategies in Immunotherapy for Non-Small-Cell Lung CancerPatrick M. Forde, Kim A. Reiss, Amer M. Zeidan, and Julie Brahmer - Sustained Complete Cytogenetic Remission in a Patient with Myelodysplastic Syndrome and Complex Karyotype after Ronald Sham - Adult Primary Pulmonary Primitive Neuroectodermal Tumor: molecular features and translational opportunitiesMirela Andrei, Stewart Cramer, Kramer, Amer Zeidan, and Faltas - Amer Zeidan, Patrick Forde, and Streiff. Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis. The 35th chapter in Abeloff's Edited by Niederhuber, Armitage, Doroshow, Kastan, and Tepper. Elsevier. 2013. - Amer Zeidan and Steven Gore. Management of High-Risk Myelodysplastic Syndrome. A book chapter in Myelodysplastic Syndromes, 2nd Edition. Edited by H. Joachim Deeg. Springer. 2013. - Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock and 2013 PMID: 23844446. Review [Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey](https://doi.org/10.1182/blood.v120.21.2062.2062)Zeidan A, Forde P, Bolanos-Meade J, Streiff M. Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey Blood 2012, 2062-2062. [DOI: 10.1182/blood.v120.21.2062.2062](https://doi.org/10.1182/blood.v120.21.2062.2062). [Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.3837.3837)Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes Blood 2012, 120: 3837-3837. [DOI: 10.1182/blood.v120.21.3837.3837](https://doi.org/10.1182/blood.v120.21.3837.3837). [Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.426.426)Zeidan A, Hendrick F, Friedmann E, Gore S, Baer M, Sasane M, Paley C, McNally D, Davidoff A. Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes Blood 2012, 120: 426-426. [DOI: 10.1182/blood.v120.21.426.426](https://doi.org/10.1182/blood.v120.21.426.426). [Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.971.971)Hendrick F, Davidoff A, Zeidan A, Gore S, Baer M. Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes Blood 2012, 120: 971-971. [DOI: 10.1182/blood.v120.21.971.971](https://doi.org/10.1182/blood.v120.21.971.971). [Medicare Prescription and Agents for MDS-Associated Anemia: A Medicare-Database Analysis.](https://doi.org/10.1182/blood.v120.21.3176.3176)Davidoff A, Hendrick F, Stuart B, Zeidan A, Shenolikar R, Gore S, Baer M. Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: Iron Chelation Therapy Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.](https://doi.org/10.1182/blood.v120.21.3178.3178)Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178-3178. [DOI: 10.1182/blood.v120.21.3178.3178](https://doi.org/10.1182/blood.v120.21.3178.3178). - Zeidan A, Streiff P, Hobson D, Horn P, Shermock K, Tinoco G, E. Impact of a Venous Thromboembolism Prophylaxis \"Smart Orderset\": [DOI: 10.1182/blood.v118.21.172.172](https://doi.org/10.1182/blood.v118.21.172.172). [Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,](https://doi.org/10.1182/blood.v118.21.3615.3615)Zeidan A, Carraway H, Yun H, Greer J, Karp J. Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Biology in Normal and Malignant Hematopoiesis. A book chapter in Leukemias: Principles and Practice of Therapy. Edited by H. Kantarjian and S. Faderl. Blackwell. 2011. - Zeidan A, Wetzler M. Stemcell Biology 2010, Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).](https://doi.org/10.1182/blood.v112.11.952.952)Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy P, Wang E, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior and Kevin McGrody. A case of primary meningococcal pericarditis caused by serotype Y Neisseria meningitides with rapid evolution into pericardial tamponade. Journal of General Internal Medicine, September 2008; 23(9):1532-1535. - Mediastinal mass in a patient with coronary artery disease. A medical image.Amer Zeidan [Frequent Molecular Aberrations in Normal Karyotype (NC) Leukemia Detected Genomic Hybridization.](https://doi.org/10.1182/blood.v110.11.4270.4270)Zeidan A, Gaile D, Conroy J, McQuaid D, Wang E, Deeb G, Wallace P, Sait S, Nowak N, Wetzler M. Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia 4270-4270. [DOI: 10.1182/blood.v110.11.4270.4270](https://doi.org/10.1182/blood.v110.11.4270.4270). - Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste NP-7New Haven, CT 06511 Biography Amer Zeidan, MBBS (a medical degree awarded in several countries outside the U.S.), MHS, is a hematologist who specializes in treating and researching myeloid malignancies. Myeloid malignancies occur when healthy blood cells throughout the body and in bone marrow do not mature normally and instead replicate, proliferate, or transform in other ways. Dr. Zeidan's research and clinical care focus on targeting therapies to a patient's diagnosis and working with their own immune system to counter the malignancies. At Yale Cancer Center, Dr. Zeidan is the medical director of Hematology Early Therapeutics Research, leader of the Disease Aligned Research Team (DART) for Leukemia and Myeloid Malignancies, and the assistant director of the Clinical Trials Office for hematology. His research efforts focus on finding new, active, and safe therapies for blood cancers through clinical trials. He also explores why certain standard therapies have not been as effective in practice as they have been in clinical trials, and how the performance of these therapies can be improved in the clinic. Dr. Zeidan has received many awards, including the Leukemia and Lymphoma Society Scholar in Clinical Research award and the National Cancer Institute Cancer Clinical Investigator Team Leadership award. He serves on the editorial boards of several key hematology and oncology publications, and is the author of more than 260 peer-reviewed studies and chapters of books. Titles - Associate Professor of Internal Medicine (Hematology) - Director, Early Therapeutics Research, Hematology - Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center - Chair, Protocol Review Committee (PRC) I, Yale Cancer Center - Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center - Director, Hematology Research Seminar Series, Hematology - Member, Executive Committee, Yale Cancer Center - Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center - Interim Chief, Hematologic Malignancies Education & Training - MHSJohns Hopkins University (2014) - FellowshipJohns Hopkins Hospital (2013) - InternshipRochester General Hospital (2010) - MBBSUniversity of Jordan (2001) Languages Spoken - (Arabic) - English Additional Information - Scholar in Clinical Research Award: Leukemia and Lymphoma Society (2018), (2019), (2020), (2021), (2022), (2023) - Cancer Clinical Investigator Team Leadership Award: National Cancer Institute (2018), (2019), (2020) - The Tito Bastianello Young Investigator Award: The 13th Annual International Symposium on Myelodysplastic Syndromes (2015) - Cooper Hematology Young Investigator Award: (2015) - Young Investigator Travel Grant: The Society of Oncologic Malignancy (2015), (2016) - Young Investigator Award: American Society of Clinical Oncology (2013), (2014) - Travel Award: 14th Annual Fellows and the 23rd Mayo Clinic Hematology and Oncology Reviews (2013) - Travel Grant: European Group for Blood and Marrow Transplantation (2013) - Scholarship Award: European Society of Hematology - European Group for Blood and Marrow Transplantation (2012) - Educational Grant: National Comprehensive Cancer Centers Network (2012) - 17th International Congress on Myelodysplastic Syndromes. (2023): Abstract Reviewer - King Hussein Cancer Center Research Conference (2022): Abstract Reviewer - Scientific Research Committee, King Hussein Cancer Center Research Conference (2022): Chair - King Hussein Cancer Center Research Conference (2022 - Present): Scientific Director - Yale ASH Highlights Series (2021): Director - Myelodysplastic Syndromes - Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting (2021): Abstract Reviewer - Myelodysplastic Syndromes - Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting (2021): Moderator - 30th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) (2021 - Present): Session Chair - Advanced Science Workshop on Myeloid Malignancies, Yale University (2019): Chair - 4th Annual Hematologic Malignancies Symposium, Yale University (2019): Co-Chair [An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS](http://www.ncbi.nlm.nih.gov/pubmed/36260702)Stahl M, Abdel-Wahab O, Wei AH, Savona MR, Xu ML, Xie Z, Taylor J, Starczynowski RF, S, List AF, Kutchroo V, Komrokji RS, Kim agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS Blood Advances 2023, 7: controlled trial](http://www.ncbi.nlm.nih.gov/pubmed/37311468)Platzbecker U, Della Porta D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Zhang J, Giuseppi A, Kreitz S, Pozharskaya V, Keeperman K, Rose S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and trial The Lancet 2023 [PMID: 37311468](https://pubmed.ncbi.nlm.nih.gov/37311468), [Effect of real-world polycythemia vera treated Boselli Hamadeh I, Begley R, Podoltsev N, Zeidan A, Balmaceda N, Yacoub A, Ai J, Knight T, Ragon B, Shah N, Sanikommu S, Symanowski J, Mesa R, Grunwald M. Effect of durable hematocrit control and minimal thrombotic risk in real-world polycythemia vera patients treated 41: e19080-e19080. [DOI: 10.1200/jco.2023.41.16_suppl.e19080](https://doi.org/10.1200/jco.2023.41.16_suppl.e19080). [Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating D, Jonasova A, Dimicoli-Salazar S, Tiong I, Lin C, Li J, Kreitz S, Pozharskaya V, Shetty J, Degulys A, Finelli C, Cluzeau T, Della Porta M. Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating double-blind, placebo-controlled study of imetelstat in patients (pts) D, Illmer T, Jonasova A, Belohlavkova P, Sherman L, Berry T, Dougherty S, Shah S, Sun L, Wan Y, Huang F, Komrokji R. IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) myelodysplastic syndromes (LR-MDS) relapsed/refractory [DOI: 10.1200/jco.2023.41.16_suppl.7004](https://doi.org/10.1200/jco.2023.41.16_suppl.7004). [Real-world (RW) patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).](https://doi.org/10.1200/jco.2023.41.16_suppl.7044)Zeidan A, Hernandez Donoso L, Hodzic S, Owusu H, Pathak D, Zhou S, Stein E. Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.](https://doi.org/10.1200/jco.2023.41.16_suppl.tps7079)Zeidan A, Fathi A, Issa G, Erba Corum D, Tomkinson B, Kozlek T, Leoni M, Wang E. Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. Journal Of Clinical Oncology 2023, 41: INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies](http://www.ncbi.nlm.nih.gov/pubmed/37290996)Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care in Patients With Advanced Hematologic Malignancies INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies](https://doi.org/10.1016/j.clml.2023.05.002)Patel M, Donnellan W, Byrne M, Asch A, Zeidan A, Baer M, Fathi A, Kuykendall A, Zheng F, Walker C, Cheng L, Marando C, Savona M. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care in Patients With Advanced Hematologic Malignancies Clinical Lymphoma & Leukemia 2023 [DOI: 10.1016/j.clml.2023.05.002](https://doi.org/10.1016/j.clml.2023.05.002). Rotter L, Shimony S, Ling K, Chen E, Shallis R, Zeidan A, Stahl M. Epidemiology and Pathogenesis of Myelodysplastic Syndrome Treatments](http://www.ncbi.nlm.nih.gov/pubmed/37195765)Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms\u2014Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments The Journal Myelodysplastic Bewersdorf J, Stahl M, Zeidan A. Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms The Cancer - Bewersdorf J, Xie Zeidan A. Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment The Cancer Journal Patients with Acute Myeloid Leukemia/Myelodysplastic Syndrome](http://www.ncbi.nlm.nih.gov/pubmed/37166332)Allen C, Gautam S, Cheng W, Pine A, Podoltsev N, Zeidan A, Lee A, Shallis R. Impact of Prophylactic Antibacterials on Coagulation Profiles and Bleeding in Patients Bewersdorf J, Zeidan A. What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?](http://www.ncbi.nlm.nih.gov/pubmed/37037494)Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer transplant outcomes: a CIBMTR analysis in 3113AML patients](http://www.ncbi.nlm.nih.gov/pubmed/36949156)Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: and tyrosine kinase inhibitor adherence](http://www.ncbi.nlm.nih.gov/pubmed/36939371)Shallis R, Wang Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine [PMID: 36939371](https://pubmed.ncbi.nlm.nih.gov/36939371), [DOI: 10.1182/bloodadvances.2022009074](https://doi.org/10.1182/bloodadvances.2022009074). [Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs.](http://www.ncbi.nlm.nih.gov/pubmed/36919991)Schukow C, Zeidan A, Loghavi S. Including International Medical Graduates in Diversity, Equity, and Inclusion Conversations Among Pathology Training Programs. Archives Of Pathology & Laboratory Medicine 2023, 147: 631-633. [PMID: 36919991](https://pubmed.ncbi.nlm.nih.gov/36919991), [DOI: in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)](http://www.ncbi.nlm.nih.gov/pubmed/36934059)Bewersdorf J, Xie Z, Bejar R, Borate S, Griffiths E, Halene S, Hasserjian R, Hourigan C, Kim T, Komrokji R, Kuchroo V, List A, Loghavi S, Majeti G, Sekeres M, Stahl M, Starczynowski D, Steensma D, Taylor J, Abdel-Wahab O, Xu M, Savona M, Wei A, Zeidan A. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for Hydroxyurea](http://www.ncbi.nlm.nih.gov/pubmed/35917456)Wang R, Shallis RM, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS A, Giagounidis A, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Santini V. STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS](http://www.ncbi.nlm.nih.gov/pubmed/36805300)Frumm S, Shimony S, Stone R, DeAngelo D, Bewersdorf J, Zeidan A, Stahl M. Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS Blood Reviews 2023, 60: Zeidan A. How I treat AML incorporating the updated classifications and guidelines Blood [PMID: 36758209](https://pubmed.ncbi.nlm.nih.gov/36758209), [DOI: as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States](http://www.ncbi.nlm.nih.gov/pubmed/36732419)Zeidan A, Pollyea D, Borate U, Vasconcelos M, Bonifacio G, Chen C. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States Annals Of Z, Zeidan A. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia Expert Review [DOI: 10.1080/17474086.2023.2174521](https://doi.org/10.1080/17474086.2023.2174521). [Consensus proposal for revised Working Group response criteria for higher risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36724453)Zeidan A, Platzbecker U, Bewersdorf J, Stahl M, Ad\u00e8s Borate U, Bowen D, Buckstein R, Brunner A, H, N, Witte DeZern Efficace Garcia-Manero Garcia G, Scheinberg P, Stauder R, Van de Loosdrecht A, Wei A, Sekeres M, Fenaux P. Consensus proposal for revised International Working Group response criteria for higher risk myelodysplastic syndromes Norsworthy K, Garcia J, de Claro R, Theoret M, Jen E, Ehrlich L, Zeidan A, Komrokji R. Considerations for Drug Development in Myelodysplastic Research patterns and real-world effectiveness rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.](http://www.ncbi.nlm.nih.gov/pubmed/36655436)Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: analysis. Haematologica MDS Fenaux Buckstein R, Santini V, D\u00edez-Campelo M, Yucel A, Tang D, Fabre S, Zhang G, Zoffoli R, Ha X, Miteva D, Hughes C, Komrokji R, Zeidan A, Garcia-Manero G. Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in A. Advances in myelodysplastic syndromes: promising novel agents and combination strategies Expert 2023, 16: A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, J, Giuseppi AC, Kreitz S, Pozharskaya Keeperman S, Cluzeau T, Fenaux P, Garcia-Manero G. Efficacy and randomised controlled trial. Lancet. 2023 Jun 9:S0140-6736(23)00874-7. doi: 10.1016/S0140-6736(23)00874-7. Online ahead of print. PMID: 37311468 - Patel MR, Donnellan W, Byrne M, Asch AS, Zeidan AM, Baer MR, Fathi AT, Kuykendall AT, Zheng F, Walker C, Cheng L, Marando C, Savona MR. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With With Advanced L, G, Chen C. Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Ann Hematol. 2023 Jun 21. doi: 10.1007/s00277-023-05327-x. Online ahead of print. PMID: 37341779 - Gurnari C, Xie Z, Zeidan A. How I Manage Transplant Ineligible Patients with Myelodysplastic intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/36493798)Bewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy](http://www.ncbi.nlm.nih.gov/pubmed/36437356)Zeidan A, Bewersdorf J, Hasle V, Shallis R, Thompson E, de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B. Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes myelodysplastic syndrome with excess blasts should be approached as a single entity](http://www.ncbi.nlm.nih.gov/pubmed/36397669)Shallis R, Daver N, Altman J, Hasserjian R, Kantarjian H, Platzbecker U, Santini V, Wei A, D, Zeidan A. TP53altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity Cancer 2022, 129: 175-180. a response criterion in myelodysplastic syndromes (MDS)](http://www.ncbi.nlm.nih.gov/pubmed/36379923)Brunner A, Gavralidis A, Ali N, Hunter A, Komrokji R, Zeidan A, Sallman D. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2022-158465)Bewersdorf J, Patel Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients (HMA) Failure](https://doi.org/10.1182/blood-2022-158626)Bewersdorf J, Shallis R, Sharon E, Caldwell A, Wei W, Yacoub A, Madanat Y, Zeidner J, Altman J, Odenike O, Yerrabothala S, Kovacsovics T, Podoltsev N, Halene S, Little R, Piekarz R, Gore S, Kim T, Zeidan A. A Multi-Center Ib Trial of Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Lymphoma (MCL): A Population-Based Analysis](https://doi.org/10.1182/blood-2022-164959)Di M, Long Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Neoplasms Treated with Ruxolitinib](https://doi.org/10.1182/blood-2022-165156)Stempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical (AML) V, Shallis R, Thompson E, Lopes de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B, Zeidan A. Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic (HR-MDS)](https://doi.org/10.1182/blood-2022-158592)Bewersdorf V, Shallis R, Thompson E, Lopes de Menezes D, Rose S, Boss I, Halene S, Haferlach T, Fox B, Zeidan A. Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) Responses with Luspatercept in the Study](https://doi.org/10.1182/blood-2022-157486)Platzbecker U, Santini V, Komrokji D, Pozharskaya V, Ha X, Nadal J, Fenaux P. Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept Blood 2022, 140: 9808-9810. [DOI: 10.1182/blood-2022-157486](https://doi.org/10.1182/blood-2022-157486). [Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST Study](https://doi.org/10.1182/blood-2022-157487)Platzbecker A, Garcia-Manero V, Ha X, Nadal J, Miteva D, Fenaux P. Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from [Overall Survival and Progression-Free Following Luspatercept Treatment in the MEDALIST Trial](https://doi.org/10.1182/blood-2022-157489)Santini V, Fenaux P, Zeidan A, Komrokji R, Buckstein X, Miteva D, Yucel A, Nadal J, Platzbecker U. Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial Blood 2022, 140: 4079-4081. [DOI: 10.1182/blood-2022-157489](https://doi.org/10.1182/blood-2022-157489). [Treatment Patterns Initiating Oral Decitabine and Cedazuridine a Real-World Setting](https://doi.org/10.1182/blood-2022-157926)Zeidan A, Divino V, DeKoven M, Wang E, Chen J, Salimi T, Epstein R. Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or with Sabatolimab Added to Hypomethylating Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2022-158612)Zeidan A, Ando K, Rauzy O, Turgut M, Cairoli R, Hou H, Kwong Y, Arnan Sangerman M, Meers Pullarkat F, J, Marques Ramos P, Fenaux P, Miyazaki Primary Results of Stimulus-MDS1: Randomized, Placebo-Controlled Phase II Study with Sabatolimab Added to Hypomethylating (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Systematic Review and Meta-Analysis](https://doi.org/10.1182/blood-2022-158622)Bewersdorf J, Grimshaw A, Platzbecker U, Fenaux P, Sekeres M, Zeidan A, Stahl M. International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents - a Blood 2022, 140: 9811-9812. [DOI: 10.1182/blood-2022-158622](https://doi.org/10.1182/blood-2022-158622). [Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2022-160002)Zeidan A, Cheng W, Kamalakar R, Miller C, Bui C, Montez M, Yee T, Wu Z, Huntington S. Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia Blood 2022, 140: 3282-3283. Adult U, Fenaux Giagounidis A, Y, Sekeres M, Xiao Z, Sanz G, Van Hoef M, Ma F, Hertle S, Marques Ramos P, Zeidan A. Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-M) in Adult mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis](https://doi.org/10.1182/blood-2022-166692)Zeidan A, Gautam S, Yu R, Lan Z, Grinblatt D, ElSouda D, Spalding J, Block A, Touya M, Pandya B. Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)](https://doi.org/10.1182/blood-2022-167259)Zeidan A, DeZern A, Borate U, Kobata K, Ide S, Sabo J, Marques Ramos P, Sun H, Lyons R, Garcia-Manero G. Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents](https://doi.org/10.1182/blood-2022-167360)Zeidan A, Tsai S, Karimi M, Schmier J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Understanding What Matters to Myelodysplastic Syndrome Patients - a Study of Preferences for Treatments with Hypomethylating Agents Blood 2022, 140: 10847-10848. [DOI: 10.1182/blood-2022-167360](https://doi.org/10.1182/blood-2022-167360). [Imetelstat Achieved Prolonged, Continuous Heavily Transfused Non-Del(5q) Lower-Risk Study](https://doi.org/10.1182/blood-2022-169050)Platzbecker Komrokji V, Van Eygen K, Raza A, Germing U, Berry T, Dougherty S, Shah S, Sun L, Huang F, Feller F, Wan Y, Ikin A, Sherman L. Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk [DOI: 10.1182/blood-2022-169050](https://doi.org/10.1182/blood-2022-169050). [How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform](https://doi.org/10.1182/blood-2022-170376)Moseley A, Freidlin B, Shallis Zeidan Little R, Erba H, Leblanc M, Othus M. How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within Platform Blood 2022, 140: 8932-8933. [DOI: 10.1182/blood-2022-170376](https://doi.org/10.1182/blood-2022-170376). [Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)](https://doi.org/10.1182/blood-2022-157326)Liu H, Sharon E, Karrison T, Zha Y, Fulton N, Streicher H, Sweet K, Yaghmour G, Liu J, Jonas B, Schimmer A, Grant S, Zeidan A, Hildebrandt G, Hourigan C, Lowrey C, Mattison R, Palmisiano N, Salhotra A, Tzachanis D, Baer M, Lin T, Patel P, Chen H, Stadler W, Odenike O, Larson R, Gajewski T, Stock W. Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy Baseline Transfusion Status](https://doi.org/10.1182/blood-2022-157666)Zeidan A, Ng C, Yellow-Duke A, Lamarre N, Cheng W, Ma E. Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By 10.1182/blood-2022-157666](https://doi.org/10.1182/blood-2022-157666). [Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2022-158276)Zeidan A, Mosher K, Souza S, Mirakhur B, Keer H, Taylor J. Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal Cytopenias](https://doi.org/10.1182/blood-2022-162367)Xie Z, Smith A, Komrokji R, Al Ali N, Patel A, Saygin C, Zeidan A, Bewersdorf J, Kishtagari A, Zeidner J, Coombs C, Madanat Y, Foran J, Badar T, Desai P, Tsai C, Griffiths E, Al Malki M, Amanam I, Lai C, Deeg J, Ades L, Arana Yi C, Osman A, Dinner S, Abaza Y, Chandhok N, Soong D, Taylor J, Brunner A, Carraway H, Singh A, Geyer S, Padron E, Patnaik M, Savona M, Al-Kali A. The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Treated in the Ascertain Trial (ASTX727-02)](https://doi.org/10.1182/blood-2022-163841)Savona M, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg J, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian A, O'Connell C, Roboz G, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Oganesian A, Chan W, Hao Y, Azab M, Garcia-Manero G. Survival in Bi-Allelic TP53 TP53 mut) MDS Subjects Treated Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program](https://doi.org/10.1182/blood-2022-169074)Zeidan A, Fradette C, Rozova A, Toiber Temin N, Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program Blood 140: Trials Network Precision Medicine Initiative](https://doi.org/10.1182/blood-2022-169307)Little R, Othus M, Assouline S, Ansher S, Atallah E, Lindsley R, Freidlin B, Gore S, Harris L, Hourigan C, Ivy S, Jiwani S, Langan E, Luger D, Perales M, Radich J, Ramineni B, Salk J, Stiff P, Stock W, Stone R, Uy G, Williams P, Wood B, Worthington K, Yee L, Zeidan A, Zhang J, Litzow M, Erba H. Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network 2022, 9057-9060. patients with relapsed or refractory syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36309981)Zeidan AM, Borate O, Watson AM, Krishnadasan R, Bajel A, Naqvi K, Zha J, Cheng W, Zhou Y, Hoffman D, Harb JG, Potluri J, GarciaManero G. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or Kim TK, Kim N, Hourigan CS, Dela Porta MG, Stahl M, Steensma D, Xu Odenike Carraway H, Fenaux P, Nazha A, Komrokji R, S, Xie Z, Hasserjian R, Savona M, Bennett JM. Differences in coming of age](http://www.ncbi.nlm.nih.gov/pubmed/36357283)Xie Z, Chen E, Stahl M, Zeidan A. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk entity with unique unmet Loghavi S, acute myeloid leukemia: a distinct genetic entity with unique unmet CIBMTR analysis in 3113 AML patients](http://www.ncbi.nlm.nih.gov/pubmed/36310182)Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, Bacher U, Badar T, Badawy S, Battiwalla M, Bejanyan N, Bhatt V, Brown V, Castillo P, Cerny J, Copelan E, Craddock C, Dholaria B, Perez M, Ebens C, Gale R, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Iqbal M, Jamy O, Kharfan-Dabaja M, Khera N, Lazarus H, Lin R, Modi D, Nathan S, Nishihori T, Patel S, Pawarode A, Saber W, Sharma A, Solh M, Wagner J, Wang T, Williams K, Winestone L, Wirk B, Zeidan A, Hourigan C, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf D. Impact of pre-transplant induction and consolidation cycles on allogeneic transplant myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors](http://www.ncbi.nlm.nih.gov/pubmed/36287540)Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/36266326)Zeidan AM, Bewersdorf CS, DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML).](http://www.ncbi.nlm.nih.gov/pubmed/36163756)Stahl M, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Bewersdorf JP. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML). Clinical Lymphoma, Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML).](http://www.ncbi.nlm.nih.gov/pubmed/36163849)Zeidan AM, Westermann J, Kovacsovics T, Assouline Schuh AC, Kim HJ, Macias GR, Sanford D, Luskin MR, Stein EM, Malek K, Lyu J, Stegert M, Esteve J. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid Leukemia (ND AML). Clinical The DA, Santini V, Sanz GF, Sekeres MA, AH, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. The Myelodysplastic Syndromes Studies Clinical Trial Program. Clinical Lymphoma, Myeloma Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups.](http://www.ncbi.nlm.nih.gov/pubmed/36163976)Alrawabdeh J, Alzu'bi M, Hamadneh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups. Clinical Lymphoma, Myeloma Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/s2152-2650(22)00747-9)Zeidan A, Westermann J, Kovacsovics T, Assouline Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2152-2650(22)00761-3)Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. Poster: AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups](https://doi.org/10.1016/s2152-2650(22)00945-4)Alrawabdeh J, Alzu'bi M, Hamadneh MDS-529 The Prognostic Value of the Endothelial Activation and Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups Clinical The Program](https://doi.org/10.1016/s2152-2650(22)00947-8)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma The Myelodysplastic Syndromes Studies on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia (AML)](https://doi.org/10.1016/s2152-2650(22)01214-9)Stahl M, Shallis R, Derkach A, Goldberg A, Stein A, Stein E, Marcucci G, Zeidan A, Shimony S, DeAngelo D, Stone R, Aldoss I, Ball B, Bewersdorf J. AML-055 Outcomes Based on Sequential Use of Venetoclax Based Therapy and Targeted Therapy in Acute Myeloid Leukemia Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/s2152-2650(22)01303-9)Zeidan A, Westermann J, Kovacsovics T, Assouline Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Diagnosed Acute Myeloid The Program](https://doi.org/10.1016/s2152-2650(22)01420-3)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. The Myelodysplastic Syndromes Studies Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups](https://doi.org/10.1016/s2152-2650(22)01428-8)Alrawabdeh J, Alzu'bi M, Hamadneh H. MDS-529 The Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score, Platelet-to-Lymphocyte Ratio (PLR), and Neutrophil-to-Lymphocyte (NLR) in Myelodysplastic Syndrome Patients in Jordan after Adjusting for IPSS-R Risk Groups Clinical medicine and immunomodulatory drugs: a focus on higher-risk disease](http://www.ncbi.nlm.nih.gov/pubmed/36045390)Mohty R, A, Brissot Zeidan A, Mohty M. Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease patients with acute myeloid leukemia previously treated with venetoclax](http://www.ncbi.nlm.nih.gov/pubmed/36108424)Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Efficacy of FLT3 and IDH1/2 inhibitors in patients with acute myeloid leukemia previously treated requires a evaluation](http://www.ncbi.nlm.nih.gov/pubmed/35984499)Stempel JM, Podoltsev NA, Zeidan AM, Lee AI, Shallis RM. Concealed by the convenient: acquired von Willebrand syndrome in myeloproliferative neoplasm requires CHIPing away the progression potential of CHIP: A new reality in the making 101001. decitabine in patients with AML ineligible for intensive chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/35507690)Zeidan AM, Fenaux P, Gobbi Thomas X, JP, Keer H, Hao Y, Azab M, D\u00f6hner H. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible Buckstein RJ, Santini V, Shetty JK, Ito R, Zhang J, Zhang G, Ha X, Backstrom JT, Komrokji Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.](http://www.ncbi.nlm.nih.gov/pubmed/35734924)Komrokji RS, Carraway HE, Germing dose escalation and randomized trial of BI 836858 in patients with rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.](https://doi.org/10.1200/jco.2022.40.16_suppl.7554)Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, S, Podoltsev N, Zeidan A, Shallis R. Body mass index and venetoclax-hypomethylating agent induction therapy for acute AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000845168.01159.c0)Zeidan A, Pollyea D, Borate G, T, C. P570: REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS care regimens in older patients with late-stage IDH2 Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Zeidan A, Chen C, Lord-Bessen J, Yu P, Shi L, Guo S, Bluemmert I, Yu X, Hasan M, Martin Regueira P, De Botton S. Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage IDH2 relapsed or with lower-risk myelodysplastic syndromes (LR-MDS) R, Miteva D, Keeperman K, Holot N, Zhang J, Hughes C, Rosettani B, Yucel A, Platzbecker U. Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from 40: 7056-7056. Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng W, Bui C, Svensson A. P766: CLINICAL OUTCOMES IN PATIENTS THE MYELODYSPLASTIC SYNDROMES IN PROGRAM](https://doi.org/10.1097/01.hs9.0000846032.37876.c9)Zeidan Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Ma G. THE MYELODYSPLASTIC SYNDROMES 6: 682-683. [DOI: STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000845216.33320.a2)Zeidan A, Westermann J, Kovacsovics T, Assouline S, Schuh A, Kim H, Macias G, Sanford D, Luskin M, Stein E, Malek K, Lyu J, Stegert M, Esteve J. P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS 6: 481-482. IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431607)Zeidan A, Divino V, DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) J, Rosettani B, Yucel A, Platzbecker U. P778: LONG-TERM UTILIZATION AND BENEFIT OF LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC MF, Halene S, Zeidan AM. Are We Moving the Needle for Patients with Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35729009)Zeidan AM, Tsai JH, Karimi J, Jayade S, Zormpas E, Hassan A, Ruiters D, Anthony C, Hill K, Wert T, Botteman M. Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35488900)Sekeres MA, Schuster Breems D, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang ES, Ching K, O'Brien T, Gallo Stampino C, Ma WW, Kudla A, Chan G, Zeidan AM. A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/35614009)Zeidan AM, Joshi N, Kale H, Wang WJ, S, Salimi T, Epstein RS. Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Beach C, Copeland WB, Thompson E, Fox BA, Hasle VE, Hellmann A, Taussig D, Tormo M, Voso MT, Cavenagh J, O'Connor T, Previtali A, Rose S, Silverman LR. Azacitidine and Durvalumab in First-line Treatment of Elderly Patients Therapy for Higher-Risk Myelodysplastic Syndromes](http://www.ncbi.nlm.nih.gov/pubmed/34972214)Zeidan AM, Boss I, Beach C, Copeland WB, Thompson E, Fox BA, Hasle VE, Ogasawara K, Cavenagh J, Silverman LR, Voso MT, Hellmann A, Tormo M, O'Connor T, Previtali A, Rose S, Garcia-Manero G. A Randomized Phase 2 Trial of acute myeloid leukemia.](http://www.ncbi.nlm.nih.gov/pubmed/35298594)Bewersdorf JP, Patel KK, Goshua G, Shallis RM, Huntington SF, Zeidan AM. Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with MDS/AML resistant to targeted inhibitors of mutant IDH1/2](http://www.ncbi.nlm.nih.gov/pubmed/35273342)Gbyli R, Song Y, Liu W, Gao Y, Biancon G, Chandhok NS, Wang X, Fu X, Patel A, Sundaram R, Tebaldi T, Mamillapalli P, Zeidan AM, PARP inhibition in IDH1/2 mutant MDS/AML of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia](https://doi.org/10.1016/s2666-6367(22)00329-3)Mirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev R, Perrault S, M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia Therapy 2022, 28: s139-s140. [DOI: [A Phase Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies](http://www.ncbi.nlm.nih.gov/pubmed/35260349)Zeidan AM, Cook RJ, Bordoni R, Berenson S, Zhou G, Asatiani E, Srinivas N, Savona MR. A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies Patients with Acute Promyelocytic Leukemia in the United States](http://www.ncbi.nlm.nih.gov/pubmed/34724703)Bewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/34981142)Zeidan AM, DeAngelo DJ, Palmer J, Seet CS, Tallman Wei X, Raymon H, Sriraman P, Kopytek S, Bewersdorf JP, Burgess MR, Hege K, Stock W. Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute Zeidan and syndromes. In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology (Cancer Principles and Practice of Oncology). Twelfth Edition. Wolters Kluwer. 2022. [The Current Understanding Treatment Paradigm Newly-Diagnosed TP53-Mutated Acute Myeloid Leukemia](https://doi.org/10.3390/hemato2040051)Shallis R, Stahl M, Bewersdorf J, Zeidan A. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Patel Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid Ilhan O, Sekeres MA, Zeidan AM, JT, in lower-risk myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial](http://www.ncbi.nlm.nih.gov/pubmed/34749571)Zeidan AM, Qi CZ, Yang H, Garnham A, Shah MV, Pandya BJ. salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial Leukemia Acute Leukemia](https://doi.org/10.1182/blood-2021-144992)Bewersdorf J, Goshua G, Patel K, Shallis R, S, Zeidan A. Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to 2021, 138: 113-113. [DOI: 10.1182/blood-2021-144992](https://doi.org/10.1182/blood-2021-144992). [Evaluation of International Working Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Frontline Setting](https://doi.org/10.1182/blood-2021-146331)Bewersdorf J, Wei W, Jaiani A, Patel P, Mehta R, Neparidze N, Shallis R, Podoltsev N, Brunner A, Zeidan A. Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with 10.1182/blood-2021-146331](https://doi.org/10.1182/blood-2021-146331). [Survival Kinase A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2021-151066)Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary \"Real World\" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States Blood 2021, 138: 282-282. [DOI: 10.1182/blood-2021-151066](https://doi.org/10.1182/blood-2021-151066). [Characteristics and Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study](https://doi.org/10.1182/blood-2021-146254)Xie Z, Hyun M, Komrokji R, Zeidan A, Madanat Y, Zeidner J, Coombs C, Griffiths E, Lai C, Kishtagari A, Foran J, Badar T, Arana Yi C, Desai P, Ades L, Osman A, Taylor J, Deeg H, Brunner A, Carraway H, Al Ali N, Bewersdorf J, Prebet T, Singh A, Tsai C, Chandhok N, Soong D, Patnaik M, Savona M, Al-Kali A. Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large 2021, 138: Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2021-151988)Ball S, Jain A, Aguirre L, Al Ali N, Bewersdorf J, Hayden A, Siddon A, Lykon J, Madarang E, Sallman D, Padron E, Sweet K, Lancet J, Watts J, Swoboda D, Pollyea D, Zeidan A, Komrokji R. Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia Blood 2021, 138: 2331-2331. [DOI: to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)](https://doi.org/10.1182/blood-2021-145015)Zeidan A, Roopcharan K, Radich J, Bewersdorf J, Bhatt V, Sharon E, Little R, Gore S, Caldwell A, Luger S, Litzow M. Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Longer-Term Follow-up of from the Ascertain Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611)Garcia-Manero McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Savona M. Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of PMC8701611](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701611), to Hypomethylating Agent Use](https://doi.org/10.1182/blood-2021-144852)Zeidan A, Divino DeKoven M, Shah D, Wang E, Bey D, Salimi T, Epstein R. Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes Onvansertib, in Combination Leukemia Erlander M, Ruffner K, Wang E. Predictive Biomarkers Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination Syndromes (HR-MDS): The MDS Studies in Program](https://doi.org/10.1182/blood-2021-145626)Zeidan A, Al-Kali A, Borate DeZern U, Sallman D, Santini V, Sanz G, Sekeres M, Wei A, Xiao Z, Van Hoef M, Nourry-Boulot C, Sadek I, Bengoudifa B, Sachs J, Garcia-Manero G. Sabatolimab (MBG453) Higher-Risk Syndromes (HR-MDS): The MDS Studies in 138: 4669-4669. [DOI: 10.1182/blood-2021-145626](https://doi.org/10.1182/blood-2021-145626). Syndrome](https://doi.org/10.1182/blood-2021-145646)Zeidan A, Borate U, Pollyea Garcia J, Filshie R, Odenike O, Watson A, Krishnadasan R, Bajel A, Naqvi K, Zha J, Hogdal L, Zhou Y, Hoffman D, Kye S, Garcia-Manero G. Venetoclax and Azacitidine in the Treatment of 2021, of Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Komrokji R, Zeidan A, Garcia-Manero G, Buckstein R, Rose S, Fabre S, Miteva D, Zhang J, Yucel A, Hughes C, Fenaux P. Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes Thompson E, Lopes de Menezes D, Rose S, Boss I, Fox B. Immune and Epigenetic Landscape of TP53- mutated Acute Clonal Cytopenias of Significance Z, Campestri G, Lasho T, Finke C, Li M, Binder M, Robertson K, Fernandez J, Hyun M, Komrokji R, Zeidan A, Bewersdorf J, Zeidner J, Coombs C, Madanat Y, Griffiths E, Lai C, Savona M, Shah M, Litzow M, Tefferi A, Mangaonkar A, N, Al-Kali A, Patnaik M. Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Lower-Intensity in Randomized, Phase 3 IDHentify Trial](https://doi.org/10.1182/blood-2021-147593)DiNardo C, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Zeidan A, Bluemmert I, Yu X, Hasan M, Martin-Regueira P, de Botton S. Outcomes for Patients Other Lower-Intensity Therapies in Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not Eligible Intensive Chemotherapy (IC)](https://doi.org/10.1182/blood-2021-147601)DiNardo C, Dohner H, Zeidan A, Schuh A, Vyas P, Stein E, Wei A, de Botton S, Chen C, Lord-Bessen J, Martin-Regueira P, Lersch F, Gong J, Guo S, Shi L, Montesinos P. Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (m IDH2 ) Acute Myeloid Leukemia (AML) Not [DOI: 10.1182/blood-2021-147601](https://doi.org/10.1182/blood-2021-147601). As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States](https://doi.org/10.1182/blood-2021-147926)Zeidan A, Pollyea D, Borate U, Vasconcelos G, Chen C. Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States Blood 2021, 138: 277-277. [DOI: 10.1182/blood-2021-147926](https://doi.org/10.1182/blood-2021-147926). [Evaluating Complete Remission with a Response Criterion in Myelodysplastic Syndromes (MDS)](https://doi.org/10.1182/blood-2021-151815)Brunner A, Gavralidis A, Al Ali N, Komrokji R, Zeidan A, Sallman D. Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Subgroup from the Ascertain Phase 3 Study](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701430)Savona M, McCloskey J, Griffiths E, Yee K, Zeidan A, Al-Kali A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Garcia-Manero G. Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain mutant-IDH2 myeloid leukaemia (AG221-AML-005): a trial](http://www.ncbi.nlm.nih.gov/pubmed/34672961)DiNardo CD, Schuh AC, Stein EM, Montesinos P, Wei AH, de Botton S, Zeidan AM, Fathi Kantarjian HM, Bennett JM, Frattini MG, Martin-Regueira P, Lersch F, Gong J, Hasan M, Vyas P, D\u00f6hner H. Enasidenib plus azacitidine versus azacitidine alone in patients newly mutant-IDH2 myeloid leukaemia (AG221-AML-005): a single-arm, phase Treatment](http://www.ncbi.nlm.nih.gov/pubmed/34674983)Zeidan AM, Jayade S, Schmier J, Botteman M, Hassan A, Ruiters D, Hill K, Joshi N. Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Myelodysplastic (MDS)](https://doi.org/10.1016/s2152-2650(21)01452-x)Zeidan I, Sabo J, Purkayastha D, Ramos P, Sun H, Lyons R, Garcia-Manero G. Poster: MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very Myelodysplastic (MDS)](https://doi.org/10.1016/s2152-2650(21)01808-5)Zeidan I, Sabo J, Purkayastha D, Ramos P, Sun H, Lyons R, Garcia-Manero G. MDS-364: STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES](https://doi.org/10.1016/j.leukres.2021.106681.52)Zeidan A, Garcia J, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, Zhou Y, Naqvi K, Kye S, Manero G. P53 Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III PHASE 3 VERONA STUDY ASSESSING THE SAFETY AND EFFICACY OF VENETOCLAX WITH AZACITIDINE IN PATIENTS WITH NEWLY Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE](https://doi.org/10.1016/j.leukres.2021.106681.10)Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. P10 Topic: AS03-Health Economics & Outcome Research/AS03a-Cost of care HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES Lu W, Shallis R, Winer with myelofibrosis: A systematic review and meta-analysis.](https://doi.org/10.1200/jco.2021.39.15_suppl.7045)Bewersdorf J, Sheth A, Vetsa Grimshaw R, Tallman M, R, Zeidan A, Stahl M. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis. for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysis.](https://doi.org/10.1200/jco.2021.39.15_suppl.6587)Dhakal P, Lyden E, Gundabolu K, Zeidan A, Loh K, Fisher A, Bhatt V. Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) higher-risk myelodysplastic syndromes.](https://doi.org/10.1200/jco.2021.39.15_suppl.7043)Zeidan A, Joshi N, Kale H, Wang W, Corman S, Hill K, Salimi T, Epstein R. Predictors agent discontinuation with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes.](https://doi.org/10.1200/jco.2021.39.15_suppl.tps7054)Zeidan A, Garcia J, Fenaux P, Platzbecker U, Miyazaki Y, Xiao Z, Zhou Y, Naqvi K, Kye S, Garcia-Manero G. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk imetelstat in transfusion-dependent subjects with IPSS low or M, Savona M, Madanat Y, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Rizo A, Berry T, Feller F, Santini V. IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or syndromes that are S. Acute Myeloid Leukemia Leading to Central Diabetes Insipidus Journal Of Buccisano F, Sallman D, Mazzucato M, Madden L, Martini M, Van Breda E, Dolcetti R, Busca A, Cook G, Onida F, Versari A, Kiladjian J, Walter R, Garderet L, Robin M, Signore A. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2 Hemato 2021, 2: 79-88. [DOI: 10.3390/hemato2010004](https://doi.org/10.3390/hemato2010004). - Sharma A, Martin Abid M, Bloomquist J, Chemaly R, Dandoy C, Gauthier J, Gowda M, Seropian S, Shaw B, Tuschl E, Zeidan A, Riches M, Shah G. 5 COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study E. Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Hemato 2021, 2, 79-88. - Rory M. Shallis,Maximilian Stahl, Jan Philipp Bewersdorf and Amer M. Zeidan. The Current Understanding of and Treatment Paradigm for Newly-Diagnosed TP53-Mutated Acute Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia](http://www.ncbi.nlm.nih.gov/pubmed/32998961)Zeidan AM, Ridinger M, Lin TL, Becker Schiller Patel PA, Spira AI, Tsai ML, Samu\u00eblsz E, Silberman SL, Erlander M, Wang ES. A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Clinical Cancer Zeidan AM. A complex karyotype and a genetic mutation in acute myeloid leukaemia Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients Trial in Progress: Glad-AML - a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Prozora Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia Patients with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2020-139468)Wang R, Shallis R, Bewersdorf J, Zeidan A, Huntington X, Podoltsev N. Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 10.1182/blood-2020-139468](https://doi.org/10.1182/blood-2020-139468). [Contemporary Practice Patterns of Use Among Older Patients with Chronic Myeloid Leukemia in the United States](https://doi.org/10.1182/blood-2020-139531)Shallis R, Wang R, Bewersdorf J, Zeidan A, Huntington S, Davidoff A, Ma X, Podoltsev N. Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood 2020, 136: 44-45. [DOI: 10.1182/blood-2020-139531](https://doi.org/10.1182/blood-2020-139531). - Davidoff Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2020-139668)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia of PD-1 to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy](https://doi.org/10.1182/blood-2020-139752)Zeidan A, Boddu P, Wood B, Zelterman D, Little R, Ivy S, Caldwell A, Sanchez-Espiridion B, Alatrash G, Sharon E, Radich J. Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy Blood 2020, 136: 11-12. [DOI: 10.1182/blood-2020-139752](https://doi.org/10.1182/blood-2020-139752). [Clinical Efficacy and Safety 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330281)Savona E, Yee K, Al-Kali A, Zeidan A, Deeg H, Patel P, Sabloff M, Keating M, Dao K, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern A, O'Connell C, Roboz G, Busque L, Wells R, Amin H, Randhawa J, Leber B, Hao Y, Keer H, Azab M, Garcia-Manero G. Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) in Patients (Pts) with Higher-Risk or Acute Myeloid Kim Y, Platzbecker U, Schuh A, Sekeres M, Westermann J, Xiao Z, Malek K, Scott J, Niolat J, Peyrard S, Ma F, Kiertsman F, Stegert M, Hertle S, Fenaux P, Santini V. The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial](https://doi.org/10.1182/blood-2020-136184)Pandya B, Qi C, Yang H, Garnham A, Shah M, Zeidan A. Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial Blood 2020, 136: 7-7. [DOI: 10.1182/blood-2020-136184](https://doi.org/10.1182/blood-2020-136184). [Streamline - FLT3 -Mutated Acute Myeloid A, Gilligan A, Gautam S, Grinblatt D, Elsouda D, Sullivan L, Pandya B. Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Blood 2020, 136: 30-31. [DOI: 10.1182/blood-2020-136366](https://doi.org/10.1182/blood-2020-136366). [Molecular Characterization of Clinical Response and in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine](https://doi.org/10.1182/blood-2020-136922)Daigle S, Choe S, DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, De Botton S, Stone R, Frattini M, Franovic A, Xu E, Winkler T, Wu B, Vyas P. Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated Blood 2020, AML Previously Treated with FLT3 inhibitors](https://doi.org/10.1182/blood-2020-137251)Numan Y, Abdel Rahman Z, Grenet J, Boisclair S, Bewersdorf J, Barth D, Zeidan A, Yilmaz M, Dinner S, Deutsch Y, Frankfurt O, Litzow M, Al-Kali A, Foran J, Sproat L, Jovanovic B, Daver N, Perl A, Altman J. Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)](https://doi.org/10.1182/blood-2020-137734)Zeidan A, Wang V, Radich J, Bewersdorf J, Bhatt V, Sharon E, Gore S, Luger S, Litzow M. Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171) Blood 2020, 136: 1-1. [DOI: 10.1182/blood-2020-137734](https://doi.org/10.1182/blood-2020-137734). [Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study](https://doi.org/10.1182/blood-2020-140564)Goksu S, Khatib J, Bacik Goksu B, Wang R, Patel P, Vusirkala M, Cole S, Seyhanli A, Ozer M, Collins R, Chung S, Zeidan A, Madanat Y. Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based Study Blood 2020, 136: 2-3. and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis](https://doi.org/10.1182/blood-2020-136671)Bewersdorf J, Tallman M, Cho C, Zeidan A, Stahl M. Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis Blood 2020, 136: 34-35. [DOI: 10.1182/blood-2020-136671](https://doi.org/10.1182/blood-2020-136671). [The Direct Medical Costs of Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents](https://doi.org/10.1182/blood-2020-139642)Joshi N, Kale H, Corman S, Hill K, Wert T, Zeidan A. The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents Blood [DOI: 10.1182/blood-2020-139642](https://doi.org/10.1182/blood-2020-139642). [Efficacy Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Analysis from the Medalist Study](https://doi.org/10.1182/blood-2020-137232)Komrokji R, Platzbecker U, Fenaux P, Garcia-Manero M, Zeidan A, DeZern A, Savona M, Shetty J, Ito R, Zhang G, Ha X, Sinsimer D, Backstrom J, Verma A. Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Blood 2020, 136: 13-15. [DOI: 10.1182/blood-2020-137232](https://doi.org/10.1182/blood-2020-137232). [Feasibility of Peri-Transfusion Quality with Myelodysplastic Syndromes](https://doi.org/10.1182/blood-2020-139919)Abel G, Klepin H, Magnavita R, Winer E, Zeidan A. Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with for Newly Diagnosed Acute Myeloid Leukemia](http://www.ncbi.nlm.nih.gov/pubmed/33119479)DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, D\u00f6hner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia Journal of volasertib in combination with decitabine in patients with acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/32951163)Cortes J, Podoltsev N, Kantarjian H, Borthakur M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia International Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Glasdegib + Azacitidine](https://doi.org/10.1016/s2152-2650(20)30732-1)Wang E, Bell T, Zeidan A, Bhattcharyya H, Kudla A, Chan G, Sekeres M. AML-205: Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study](https://doi.org/10.1016/s2152-2650(20)30973-3)Zeidan A, Garcia-Manero G, DeZern A, Fenaux P, Greenberg A, Mufti G, Buckstein V, Laadem A, Zhang J, Rampersad A, Sinsimer D, Louis C, Linde P, Platzbecker U, Sekeres M. MDS-179: Clinical in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study Clinical Lymphoma Myeloma & Leukemia 2020, Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the 3 MEDALIST Trial](https://doi.org/10.1016/s2152-2650(20)30971-x)Fenaux P, Santini V, Mufti G, Diez-Campelo A, Ad\u00e8s L, Verma A, Savona M, Laadem A, Ito R, Zhang J, Rampersad A, Sinsimer D, Morison J, Louis C, Linde U. MDS-171: Effects Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial Clinical Lymphoma Myeloma & Leukemia 2020, 20: s317. [DOI: 10.1016/s2152-2650(20)30971-x](https://doi.org/10.1016/s2152-2650(20)30971-x). [AML-187: STIMULUS Clinical Trial Program: Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Leukemia](https://doi.org/10.1016/s2152-2650(20)30727-8)Zeidan H, Miyazaki Y, Platzbecker U, Schuh A, Westermann J, Malek K, Scott J, Niolat J, Peyrard S, Kiertsman F, Stegert M, Fenaux P. AML-187: The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the 3 MEDALIST Trial](https://doi.org/10.1016/s2152-2650(20)30972-1)Platzbecker U, Fenaux P, Mufti G, Garcia-Manero A, Ad\u00e8s L, Verma A, Savona M, Laadem A, Ito R, Zhang J, Rampersad A, Morison J, Louis C, Linde P, Santini V. MDS-175: Assessment of Dose-Dependent with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial Clinical Lymphoma & Leukemia 2020, 20: s318. [DOI: 10.1016/s2152-2650(20)30972-1](https://doi.org/10.1016/s2152-2650(20)30972-1). [MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. MDS-280: Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence](https://doi.org/10.1016/s2152-2650(20)30733-3)Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. AML-207: Glasdegib in Combination with Azacitidine in Patients with Untreated Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion Independence Clinical Lymphoma Myeloma & Leukemia 2020, [DOI: 10.1007/978-3-030-51878-3_7](https://doi.org/10.1007/978-3-030-51878-3_7). [Special considerations in the of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts](http://www.ncbi.nlm.nih.gov/pubmed/32563283)Zeidan AM, Boddu PC, Patnaik MM, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts The receiving hypomethylating agents: a large population-based study in the United States](http://www.ncbi.nlm.nih.gov/pubmed/32433746)Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States a Medicare insured patient population: Role of initial care setting and socioeconomic status.](https://doi.org/10.1200/jco.2020.38.15_suppl.e19057)Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. [DOI: 10.1200/jco.2020.38.15_suppl.e19057](https://doi.org/10.1200/jco.2020.38.15_suppl.e19057). [Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed leukemia (ND-AML).](https://doi.org/10.1200/jco.2020.38.15_suppl.7501)Dinardo C, Schuh A, Stein E, Montesinos P, Wei A, De Botton S, Zeidan A, Fathi A, Quek L, Kantarjian H, Frattini M, Lersch F, Gong J, Franovic A, Vyas P, Dohner H. Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant -IDH2 ( mIDH2 ) newly diagnosed 2020, 38: 7501-7501. [DOI: 10.1200/jco.2020.38.15_suppl.7501](https://doi.org/10.1200/jco.2020.38.15_suppl.7501). [Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS).](https://doi.org/10.1200/jco.2020.38.15_suppl.7518)Komrokji R, Sekeres M, Zeidan Fenaux P, List Dezern A, Greenberg P, Savona M, Jurcic J, Verma A, Mufti G, Buckstein R, Santini V, Laadem A, Ito R, Zhang J, Louis C, Linde P, Garcia-Manero G. Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts 7518-7518. [DOI: 10.1200/jco.2020.38.15_suppl.7518](https://doi.org/10.1200/jco.2020.38.15_suppl.7518). [Glasdegib in combination untreated higher-risk myelodysplastic syndromes acute myeloid leukemia (AML) and chronic leukemia (CMML): Effects on marrow recovery and transfusion independence.](https://doi.org/10.1200/jco.2020.38.15_suppl.7526)Zeidan A, Schuster M, Joris M, Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Sekeres M. Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence. Journal Of Clinical Oncology 2020, 38: 7526-7526. [DOI: 10.1200/jco.2020.38.15_suppl.7526](https://doi.org/10.1200/jco.2020.38.15_suppl.7526). [Health-related syndromes E, Bell Zeidan Bhattacharyya H, Kudla A, Chan G, Sekeres M. Health-related quality of life (HRQoL) in patients higher-risk syndromes receiving glasdegib [DOI: with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.](https://doi.org/10.1200/jco.2020.38.15_suppl.7554)Zeidan A, Garcia-Manero G, Dezern A, Fenaux P, Greenberg A, Mufti G, Buckstein V, Laadem A, Zhang J, Rampersad A, Sinsimer D, Louis C, Linde P, List A, Sekeres M. Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study. Journal Of Clinical Oncology 2020, 38: 7554-7554. [DOI: 10.1200/jco.2020.38.15_suppl.7554](https://doi.org/10.1200/jco.2020.38.15_suppl.7554). [Patterns of outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States](http://www.ncbi.nlm.nih.gov/pubmed/32311013)Zeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study](http://www.ncbi.nlm.nih.gov/pubmed/32132655)Stahl M, Shallis RM, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Acu\u00f1a-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy](http://www.ncbi.nlm.nih.gov/pubmed/32100599)Shallis RM, Stahl M, Wei W, Montesinos P, Lengline Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo Acu\u00f1a-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy Leukemia use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey](http://www.ncbi.nlm.nih.gov/pubmed/32026740)Pine SM, Stone PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based L, Verma A, Savona A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji AF. Luspatercept in Patients with Lower-Risk Myelodysplastic [DOI: 10.1056/nejmoa1908892](https://doi.org/10.1056/nejmoa1908892). [Hypomethylating agent and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study](http://www.ncbi.nlm.nih.gov/pubmed/31878809)Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched (AML) or Myelodysplastic J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes [Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?](https://doi.org/10.1182/blood-2019-127277)Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. [DOI: 10.1182/blood-2019-127277](https://doi.org/10.1182/blood-2019-127277). Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Impact the for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia](https://doi.org/10.1182/blood-2019-127563)Podoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Phlebotomy and Hydroxyurea Use in Patients Agents Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)](https://doi.org/10.1182/blood-2019-128821)Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US) Blood 2019, 134: 4748-4748. [DOI: 10.1182/blood-2019-128821](https://doi.org/10.1182/blood-2019-128821). [Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study](https://doi.org/10.1182/blood-2019-126643)Zeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Study Blood 2019, 134: 116-116. [DOI: 10.1182/blood-2019-126643](https://doi.org/10.1182/blood-2019-126643). [Clinical Outcomes of Older Patients Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States](https://doi.org/10.1182/blood-2019-127398)Zeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in United States Blood 2019, 134: 646-646. [DOI: 10.1182/blood-2019-127398](https://doi.org/10.1182/blood-2019-127398). [Incidence and Risk Factors of Second Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea](https://doi.org/10.1182/blood-2019-127568)Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Infusional Cytarabine for Frontline Treatment of acute Myeloid Leukemia](https://doi.org/10.1182/blood-2019-131520)Strickland S, Podoltsev N, Mohan S, Zeidan A, Childress M, Ayers G, Byrne M, Gore S, Stuart R, Savona M. The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Blood 134: 180-180. Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study](https://doi.org/10.1182/blood-2019-123535)Zeidan A, Gilligan A, Gautam S, Hu N, Grinblatt D, Pandya B. Streamline - Study of Relapse or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study Blood 2019, 134: 5082-5082. [DOI: 10.1182/blood-2019-123535](https://doi.org/10.1182/blood-2019-123535). [Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (FLT3mut+) Qi C, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) of Gilteritinib Versus Salvage the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2019-123819)Zeidan A, Qi Pandya B, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia](https://doi.org/10.1182/blood-2019-124034)Zeidan Schuster Krauter J, Maertens J, Gyan E, Joris M, Menne T, Vyas P, Ma W, O'Connell A, Zeremski M, Kudla A, Chan G, Sekeres M. Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients Modulator, in a Phase I Dose-Escalation Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)](https://doi.org/10.1182/blood-2019-124291)Fan J, Wang H, Couto S, Yao T, Uy G, Zeidan A, Minden M, Montesinos P, DeAngelo D, Altman J, Koprivnikar J, Vyas P, Y, Bel\u00e9n Vidriales M, Gjertsen B, Buchholz T, Pourdehnad CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Relapsed or Refractory Acute of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute DeAngelo D, Palmer J, Seet C, Tallman M, Wei X, Li Y, Hock N, Burgess M, Hege K, Stock W. A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1](https://doi.org/10.1182/blood-2019-127041)Zeidan A, Miyazaki Y, Platzbecker U, F, Fenaux P. A Randomized, Double-Blind, Placebo-Controlled, II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1 Blood with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Study](https://doi.org/10.1182/blood-2019-122896)Zeidan A, Cavenagh J, Voso M, Taussig D, Tormo M, Boss I, Copeland W, Gray V, Previtali A, O'Connor T, Rose S, Beach C, Silverman L. Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Study Blood 2019, 134: 829-829. [DOI: 10.1182/blood-2019-122896](https://doi.org/10.1182/blood-2019-122896). [Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine](https://doi.org/10.1182/blood-2019-122980)Garcia-Manero Griffiths E, Yee K, Zeidan A, Al-Kali A, Dao K, Deeg H, Patel P, Sabloff M, Keating M, Zhu N, Gabrail N, Fazal S, Maly J, Odenike O, Shastri A, DeZern A, O'Connell C, Roboz G, Oganesian A, Hao Y, Keer H, Azab M, Savona M. Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) 10.1182/blood-2019-122980](https://doi.org/10.1182/blood-2019-122980). [Assessment of Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2019-123064)Fenaux P, Mufti G, Buckstein R, Santini R, List A, Zeidan A, Verma A, Laadem A, Ito R, Zhang J, Rampersad A, Sinsimer D, Linde P, Garcia-Manero G, Platzbecker U. Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood 2019, 134: 841-841. with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study](https://doi.org/10.1182/blood-2019-123966)Uy G, Minden M, Montesinos P, DeAngelo D, Altman J, Koprivnikar J, Vyas P, Y, Vidriales M, Gjertsen B, Esteve J, Buchholz T, Couto S, Fan J, Hanna B, Li L, Pierce D, Hege K, Pourdehnad M, Zeidan A. Clinical with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a 2019, 134: 232-232. [DOI: 10.1182/blood-2019-123966](https://doi.org/10.1182/blood-2019-123966). Study of in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Joris Krauter J, Maertens J, Gyan E, Kovacsovics T, Verma A, Vyas P, Wang E, Ma W, Zeremski M, Kudla A, Chan G, Zeidan A. A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid 177-177. [DOI: 10.1182/blood-2019-124050](https://doi.org/10.1182/blood-2019-124050). [A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome](https://doi.org/10.1182/blood-2019-124994)Zeidan A, Pollyea Garcia Borate U, Odenike O, Bajel A, Watson A, G\u00f6tze K, Nolte F, Tan P, Hong W, Dunbar M, Zhou Y, Gressick L, Ainsworth W, Harb J, Salem A, Hayslip J, Swords R, Garcia-Manero G. A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Myelodysplastic Syndrome 565-565. [DOI: Onvansertib (ONV), Decitabine Patients Acute Myeloid Leukemia (R/R AML)](https://doi.org/10.1182/blood-2019-126262)Zeidan A, Schiller G, Lin T, Becker P, Patel P, Wang E, Spira A, Tsai M, Ridinger M, Croucher P, Erlander M, Silberman S. Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), Decitabine Patients (pts) Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim II Results from an Ongoing, Randomized Study](https://doi.org/10.1182/blood-2019-130362)DiNardo C, Schuh A, Stein E, Fernandez P, Wei A, De Botton S, Zeidan A, Fathi A, Quek L, Kantarjian H, Frattini M, Lersch F, Gong J, Franovic A, MacBeth K, Vyas P, D\u00f6hner H. Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from Randomized Study Blood 2019, 134: 643-643. [DOI: 10.1182/blood-2019-130362](https://doi.org/10.1182/blood-2019-130362). [Association of provider experience and in patients with myelodysplastic syndromes receiving hypomethylating agents](http://www.ncbi.nlm.nih.gov/pubmed/31570040)Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating with relapsed/refractory acute myeloid leukaemia in phase Ib](https://doi.org/10.1093/annonc/mdz251.001)Zeidan A, Becker P, Patel P, Schiller G, Tsai M, Lin T, Wang E, Erlander M, Cortes J. 1066O Polo-like with relapsed/refractory acute Newly Diagnosed Acute Myeloid Leukemia (ND AML)](https://doi.org/10.1016/j.clml.2019.07.090)DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Wang X, Gong J, Kapsalis S, Hickman D, Zhang V, Winkler T, Daigle S, Vyas P. Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Acute Myeloid Leukemia (ND [Underutilization guidelinerecommended supportive care among older adults with multiple myeloma in the United States](http://www.ncbi.nlm.nih.gov/pubmed/31381151)Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guidelinerecommended supportive care among older adults with multiple myeloma in the United States the combination with patients with relapsed or refractory acute myeloid leukemia](https://doi.org/10.1158/1538-7445.sabcs18-ct102)Zeidan A, Becker P, Spira A, Patel P, Schiller G, Tsai M, Lin T, Ridinger M, Erlander M, Silberman S, Cortes J. Abstract CT102: Phase Ib safety, preliminary anti-leukemic activity and the combination with decitabine in patients with relapsed the combination with patients with relapsed or refractory acute myeloid leukemia](https://doi.org/10.1158/1538-7445.am2019-ct102)Zeidan A, Becker P, Spira A, Patel P, Schiller G, Tsai M, Lin T, Ridinger M, Erlander M, Silberman S, Cortes J. Abstract CT102: Phase Ib safety, preliminary anti-leukemic activity and the combination with decitabine in patients with relapsed or refractory myeloid leukemia Cancer Research 2019, 79: ct102-ct102. [DOI: 10.1158/1538-7445.am2019-ct102](https://doi.org/10.1158/1538-7445.am2019-ct102). - Zeidan A, Boddu P. Autoimmune Disorders and the Development of Myeloid Disease: Should We Always Blame the Therapy? The Hematologist 2019, 16 [DOI: 10.1182/hem.v16.4.9711](https://doi.org/10.1182/hem.v16.4.9711). [RBC transfusion independence MDS patients receiving hypomethylating agents: a population-level analysis](http://www.ncbi.nlm.nih.gov/pubmed/31170846)Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA](https://doi.org/10.1097/01.hs9.0000562388.60660.bc)DiNardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, D\u00f6hner H, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, Botton S, Kantarjian H, Stone R, Lam D, Wang X, Gong J, Kapsalis S, Hickman D, Zhang V, Winkler T, Wu B, Vyas P. PS1023 MUTANT IDH1 INHIBITOR IVOSIDENIB (AG-120) IN COMBINATION WITH AZACITIDINE LEUKEMIA HemaSphere 2019, 3: 460-461. [DOI: 10.1097/01.hs9.0000562388.60660.bc](https://doi.org/10.1097/01.hs9.0000562388.60660.bc). - Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of newly diagnosed acute myeloid leukemia (ND AML).](https://doi.org/10.1200/jco.2019.37.15_suppl.7011)Dinardo C, Stein A, Stein E, Fathi A, Frankfurt O, Schuh A, Martinelli G, Patel P, Raffoux E, Tan P, Zeidan A, de Botton S, Kantarjian H, Stone R, Lam D, Gong J, Zhang V, Winkler T, Wu B, Vyas P. Mutant IDH1 inhibitor ivosidenib (IVO; AG-120) in combination with newly diagnosed acute myeloid leukemia (ND Shallis RM, Wang R, Davidoff Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges 70-87. [PMID: 31101526](https://pubmed.ncbi.nlm.nih.gov/31101526), [DOI: 10.1016/j.blre.2019.04.005](https://doi.org/10.1016/j.blre.2019.04.005). [Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic targeting?](http://www.ncbi.nlm.nih.gov/pubmed/30861094)Vandsemb EN, Kim TK, Zeidan AM. Will deeper characterization of the landscape of immune checkpoint molecules in acute myeloid leukemia bone marrow lead to improved therapeutic Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.](http://www.ncbi.nlm.nih.gov/pubmed/30865915)Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. [PMID: the Modern Era: A Single Center Experience](https://doi.org/10.1016/j.bbmt.2018.12.796)Boddu P, Perreault S, Isufi I, Chandhok N, Kim T, Pillai M, Bar N, Prebet T, Zeidan A, Zelterman D, Seropian S, Gowda F. Allogeneic Stem Cell Transplantation for T-Cell Lymphomas in the Modern Era: A Single Center Experience Transplantation And Cellular Therapy 2019, 25: s387. [DOI: 10.1016/j.bbmt.2018.12.796](https://doi.org/10.1016/j.bbmt.2018.12.796). - Boddu P, Zeidan AM. Myeloid disorders after autoimmune disease Best Practice & hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/30636526)Zeidan AM, Klink AJ, McGuire M, Feinberg B. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes Cham. https://doi.org/10.1007/978-3-030-51878-3_7. 2020. Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis](https://doi.org/10.1182/blood-2018-99-111052)Zeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Blood 2018, 132: 370-370. [DOI: 10.1182/blood-2018-99-111052](https://doi.org/10.1182/blood-2018-99-111052). [Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort](https://doi.org/10.1182/blood-2018-99-112495)Stahl M, Wei W, Montesinos P, Lengline E, Shallis Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Rabinovich E, Yoo B, Podoltsev N, Gore S, Zeidan A. Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort Blood 2018, 132: 1428-1428. [DOI: 10.1182/blood-2018-99-112495](https://doi.org/10.1182/blood-2018-99-112495). [Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort](https://doi.org/10.1182/blood-2018-99-112974)Stahl M, Wei W, Montesinos P, Lengline E, Shallis Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Rabinovich E, Yoo B, Podoltsev N, Gore S, Zeidan A. Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort Blood 2018, 132: 4040-4040. [DOI: 10.1182/blood-2018-99-112974](https://doi.org/10.1182/blood-2018-99-112974). [Association between Oncologist Ownership and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility](https://doi.org/10.1182/blood-2018-99-115140)Huntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility Blood 2018, (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2018-99-116497)Zeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions Blood 2018, 132: 838-838. [DOI: 10.1182/blood-2018-99-116497](https://doi.org/10.1182/blood-2018-99-116497). [Use of Statins, Survival and Incidence Among Older Adults with Essential Thrombocythemia: A Population-Based Study](https://doi.org/10.1182/blood-2018-99-119118)Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based 2018, 132: 4865-4865. of Statins, Survival Older Adults with Polycythemia Vera: A Population-Based Study](https://doi.org/10.1182/blood-2018-99-119272)Podoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: with Newly-Diagnosed Acute Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database](https://doi.org/10.1182/blood-2018-99-119755)Shallis R, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt V, Sekeres Umakanthan J, Mukherjee S, Brunner A, Miller A, McMahon C, Ritchie E, Rodr\u00edguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuna Cruz E, Podoltsev N, Gore S, Zeidan A. Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database Blood 2018, 132: 3999-3999. [DOI: 10.1182/blood-2018-99-119755](https://doi.org/10.1182/blood-2018-99-119755). [Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States](https://doi.org/10.1182/blood-2018-99-119791)Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States Blood 2018, 132: 978-978. [DOI: 10.1182/blood-2018-99-119791](https://doi.org/10.1182/blood-2018-99-119791). [Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey](https://doi.org/10.1182/blood-2018-99-113888)Pine Stahl M, Steensma D, Sekeres M, Litzow M, Luger S, Stone R, Greenberg P, Bejar R, Gore S, Zeidan A. Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a 1825-1825. [DOI: 10.1182/blood-2018-99-113888](https://doi.org/10.1182/blood-2018-99-113888). Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions](https://doi.org/10.1182/blood-2018-99-110805)Fenaux P, Platzbecker U, Mufti G, Garcia-Manero J, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern A, Jurcic J, Germing P, Hellstr\u00f6m-Lindberg E, Zeidan A, Laadem A, Benzohra A, Zhang J, Rampersad A, Linde P, Sherman M, Komrokji R, List A. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions Blood 2018, 132: in Patients with (R/R) Acute Myeloid Leukemia (AML)](https://doi.org/10.1182/blood-2018-99-112590)Zeidan A, Schiller G, Spira Patel P, Tsai M, Ridinger M, Silberman S, Erlander M, Cortes J. Preliminary Safety, in Patients with Relapsed Timed Sequential Therapy (TST) for Knaus L, Ghiaur G, Showel M, DeZern A, Pratz K, Smith B, Levis M, Foster M, Coombs C, Streicher H, Karp J, Luznik L, Gojo I. Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/30413901)Zeidan AM, Giri S, DeVeaux M, Ballas SK, Duong VH. Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic on survival and risk of thrombosis among older patients with polycythemia vera](http://www.ncbi.nlm.nih.gov/pubmed/30333100)Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera anemia: Etiology, molecular pathogenesis, and is a prerequisite to taming it](http://www.ncbi.nlm.nih.gov/pubmed/30314642)Zeidan AM, Shallis RM, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it Blood Reviews 2018, 34: 1-15. [PMID: 30314642](https://pubmed.ncbi.nlm.nih.gov/30314642), [DOI: 10.1016/j.blre.2018.09.001](https://doi.org/10.1016/j.blre.2018.09.001). - Huntington W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma therapy in search of the right place](http://www.ncbi.nlm.nih.gov/pubmed/30024293)Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place Expert Review Of Hematology 2018, 11: 715-726. case series of Jehovah's Witnesses with myeloid malignancies](http://www.ncbi.nlm.nih.gov/pubmed/30088044)Shallis RM, Xu ML, Curtis SA, Medoff E, Mixon R, Folkers A, Zeidan AM. Conviction in the face of affliction: a case series of Jehovah's Witnesses with Syndromes following Zeidner JF, Blackford AL, Duffield AS, Rizzieri D, Frattini MG, Levy YM, Schroeder MA, Ferguson A, Sheldon KE, DeZern AE, Gojo I, Gore SD, Streicher H, Luznik L, Smith BD. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating MDS: clinical outcomes and their predictors in a large international patient cohort](http://www.ncbi.nlm.nih.gov/pubmed/30037803)Stahl M, DeVeaux M, de Witte A, Maciejewski Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort Blood Advances study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/30027436)Kim TK, DeVeaux M, Stahl M, Perreault Isufi Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation The genetic and molecular pathogenesis of myelodysplastic Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia](http://www.ncbi.nlm.nih.gov/pubmed/29963936)Stahl M, DeVeaux M, Montesinos N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute azacitidine therapy: are we using realistic estimates?](http://www.ncbi.nlm.nih.gov/pubmed/29891916)Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute Clinical 2018, 36: e22124-e22124. 10.1200/jco.2018.36.15_suppl.e22124](https://doi.org/10.1200/jco.2018.36.15_suppl.e22124). - Stahl M, Zeidan Inhibition in Myelofibrosis\u2014The Long of iron chelation therapy on overall survival in sickle cell disease and thalassemia: A systematic review](http://www.ncbi.nlm.nih.gov/pubmed/29635754)Ballas SK, Zeidan AM, Duong VH, DeVeaux M, Heeney MM. The effect of iron chelation therapy on overall survival in sickle cell disease and thalassemia: A systematic review American Journal AML: outcomes and their predictors in a large international patient cohort](http://www.ncbi.nlm.nih.gov/pubmed/29685952)Stahl M, DeVeaux M, Montesinos P, Itzykson Serrano J, Gore AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort Blood Advances 923-932. [PMID: 29685952](https://pubmed.ncbi.nlm.nih.gov/29685952), acute myeloid leukemia: a large U.S. web-based M, Pine JE, Litzow DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study](http://www.ncbi.nlm.nih.gov/pubmed/29649620)Stahl M, DeVeaux Montesinos P, Itzykson R, Ritchie N, Verma V, Kobbe G, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study Transplantation And Cellular Therapy 2018, 24: 1754-1758. [PMID: 29649620](https://pubmed.ncbi.nlm.nih.gov/29649620), [DOI: 10.1016/j.bbmt.2018.03.025](https://doi.org/10.1016/j.bbmt.2018.03.025). Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia Journal Of to chelate in MDS: AM. Lenalidomide in non-deletion 5q lower-risk a quarter [More less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/29435332)Shallis RM, Zeidan AM. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with in Myelofibrosis-The Long Road Ahead. JAMA oncology, Epub ahead of Print. 2018 Mar 8. doi: 10.1001/jamaoncol.2017.5802. - Natalie Uy, Michelle Nadeau, Maximilian Stahl, and Amer M. Zeidan. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic J Blood Med. 2018 10.2147/JBM.S136575. eCollection 2018. Review. PMID: 29713210 [Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.](http://www.ncbi.nlm.nih.gov/pubmed/29259002)Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States](https://doi.org/10.1182/blood.v130.suppl_1.675.675)Giri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) 675-675. [DOI: 10.1182/blood.v130.suppl_1.675.675](https://doi.org/10.1182/blood.v130.suppl_1.675.675). [A Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic Malignancies](https://doi.org/10.1182/blood.v130.suppl_1.640.640)Zeidan A, Cook R, Bordoni R, Asatiani E, Zhou G, Faivre T, Byrne M, Savona M. A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Hematologic Malignancies changing landscape or a AM. Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing localized breast cancer: A population-based study](http://www.ncbi.nlm.nih.gov/pubmed/28902882)Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box](http://www.ncbi.nlm.nih.gov/pubmed/28787256)Zeidan AM, Gore SD, Davidoff AJ. US Food and Drug Administration Black Box Warning and Its Impact on the Use of Erythropoiesis-Stimulating Agents: Thinking Outside the Box S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life Journal Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment](http://www.ncbi.nlm.nih.gov/pubmed/28758974)Gbolahan OB, Zeidan AM, Stahl M, Abu Zaid M, Farag S, Paczesny S, Konig H. Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment with higherrisk myelodysplastic syndromes in firstline MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higherrisk myelodysplastic [DOI: M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous Komrokji RS. Overcoming barriers to treating iron overload in patients with lower-risk myelodysplastic syndrome TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are lymphoma after autologous stem cell transplantation](http://www.ncbi.nlm.nih.gov/pubmed/28640385)Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Costeffectiveness analysis of consolidation with brentuximab vedotin for highrisk Hodgkin survival in older patients with chronic myelomonocytic leukemia in the United States: A large populationbased study](http://www.ncbi.nlm.nih.gov/pubmed/28621841)Zeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.](https://doi.org/10.1200/jco.2017.35.15_suppl.7057)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A Of Clinical Oncology 2017, 7057-7057. [DOI: 10.1200/jco.2017.35.15_suppl.7057](https://doi.org/10.1200/jco.2017.35.15_suppl.7057). - Huntington Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma Zeidner J, Blackford A, Rizzieri D, Frattini M, Levy M, Schroeder M, Ferguson A, Sheldon K, Dezern A, Gojo I, Gore S, Streicher H, Luznik L, Duffield A, Smith B. A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes Management of myelofibrosis: JAK inhibition and Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study](https://doi.org/10.1016/s0145-2126(17)30234-5)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Agent in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study](https://doi.org/10.1016/s0145-2126(17)30145-5)Zeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large 55: Phase Zeidner J, Blackford A, Duffield A, Rizzieri D, Frattini M, Levy M, Schroeder M, Ferguson A, Sheldon K, Dezern A, Gojo I, Gore S, Streicher H, Luznik L, Smith B. 64 A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and in a patient with advanced myelodysplastic syndrome](http://www.ncbi.nlm.nih.gov/pubmed/28220192)Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced mechanisms and clinical applications](http://www.ncbi.nlm.nih.gov/pubmed/28192601)Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium](http://www.ncbi.nlm.nih.gov/pubmed/28111463)Zeidan AM, Al Ali N, Barnard J, Padron E, Lancet JE, Sekeres MA, Steensma DP, DeZern G, Jabbour E, Garcia-Manero G, List A, Komrokji R. Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?](http://www.ncbi.nlm.nih.gov/pubmed/28094843)Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end Cancer Gore, and Amer Methqal Zeidan. An Illustrated Guide to Diagnosis and Treatment. In Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment. Edited by Ashkan Emadi, MD, PhD, Judith E. Karp, MD. Springer. 2017. - Vu H. Duong and Amer Methqal Zeidan. An Illustrated Guide to Diagnosis and Treatment. In Acute Leukemia: An Illustrated Guide to Diagnosis and Treatment. Edited by Ashkan Emadi, MD, PhD, Judith E. Karp, MD. Springer. 2017. - Wang A, Brunet CM, Zeidan AM. Barta SK, Bejar R, Bennett JM, Castro Deeg DeZern Frankfurt Head D, Horsfall Komrokji LA, BL, Walker AR, Westervelt P, DA, Smith C. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2016, with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort](https://doi.org/10.1182/blood.v128.22.1063.1063)Stahl M, Podoltsev N, DeVeaux M, Perreault S, Itzykson V, U, Montesinos Fern\u00e1ndez P, Zelterman D, Kim T, Prebet T, Gore S, Zeidan A. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort Blood 2016, 128: 1063-1063. [DOI: 10.1182/blood.v128.22.1063.1063](https://doi.org/10.1182/blood.v128.22.1063.1063). [Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study](https://doi.org/10.1182/blood.v128.22.394.394)Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study Blood 2016, 128: [Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue](https://doi.org/10.1182/blood.v128.22.1188.1188)Hui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue Blood 2016, 128: 1188-1188. [DOI: 10.1182/blood.v128.22.1188.1188](https://doi.org/10.1182/blood.v128.22.1188.1188). [Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)](https://doi.org/10.1182/blood.v128.22.2820.2820)Zeidner J, Montiel-Esparza R, Knaus H, Berglund S, Zeidan A, McCurdy S, Prince G, Gondek L, Ghiaur G, Showel M, DeZern A, Pratz K, Smith B, Levis M, Foster M, Jamieson K, Van Deventer H, Streicher H, Karp J, Luznik L, Gojo I. Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and Myelodysplastic Bone marrow failure disease scientific symposium 2016](http://www.ncbi.nlm.nih.gov/pubmed/27923195)Zeidan AM, Battiwalla M, Berlyne D, Winkler T. Aplastic Anemia and MDS International Foundation (AAMDSIF): Bone marrow failure disease scientific symposium 2016 Leukemia blood product transfusion practices among providers who care for patients with acute leukemia in the United States](http://www.ncbi.nlm.nih.gov/pubmed/27878822)Pine AB, Lee E, Sekeres M, Steensma Luger S, Stone R, Erba HP, GarciaManero G, Lee AI, Podoltsev NA, Barbarotta L, Kasberg S, Hendrickson JE, Gore SD, Zeidan AM. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States Transfusion Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate with relapsed/refractory Carraway HE, Gojo I, DeZern A, Gore SD. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities World Journal Of Stem on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC)*](http://www.ncbi.nlm.nih.gov/pubmed/27774847)DeZern AE, Zeidan AM, Barnard J, Hand W, Ali N, Brown F, Zimmerman C, Roboz GJ, Garcia-Manero G, Steensma DP, Komrokji RS, response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS of erythroblast Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/27650975)Zeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States](http://www.ncbi.nlm.nih.gov/pubmed/27558206)Zeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States Leukemia & 58: 982-985. Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes Expert Opinion On Emerging Drugs 2016, 21: 283-300. DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated Medicareenrolled patients with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/26970288)Zeidan AM, Wang R, Davidoff AJ, Ma S, Zhao Y, Gore SD, Gross CP, Ma X. Diseaserelated costs of care and survival among Medicareenrolled patients syndromes: Findings from a large national database](http://www.ncbi.nlm.nih.gov/pubmed/26914833)Fletcher SA, Cronin AM, Odejide OO, Gore AJ, Steensma DP, Abel GA. Intensity of endoflife care for patients with myelodysplastic syndromes: Findings from a large national database Cancer 2016, [PMID: 26914833](https://pubmed.ncbi.nlm.nih.gov/26914833), [DOI: Rheumatologic Manifestations of Hematologic Malignancies. Current Rheumatology Reviews. 2016 Aug 15. [Epub ahead print]. [The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions.](http://www.ncbi.nlm.nih.gov/pubmed/26008639)Hamoudeh E, Zeidan AM, Barbarotta L, Rosano N. The Interactions Between Diabetes Mellitus and Myelodysplastic Syndromes: Current State of Evidence and Future Directions. Current Reviews 2016, 12: 231-9. Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)](https://doi.org/10.1182/blood.v126.23.3285.3285)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed Leukemia: Results of a North American Web-Based Survey](https://doi.org/10.1182/blood.v126.23.4455.4455)Lee E, Smith B, Merrey J, Lee A, Podoltsev N, Barbarotta L, Litzow M, Prebet T, Luger S, A. Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based Survey Blood 2015, 126: 4455-4455. [DOI: 10.1182/blood.v126.23.4455.4455](https://doi.org/10.1182/blood.v126.23.4455.4455). [North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia](https://doi.org/10.1182/blood.v126.23.1138.1138)Pine A, Lee E, Sekeres M, Steensma D, Prebet T, DeZern A, Komrokji M, Luger S, Stone R, Erba H, Garcia-Manero G, Lee A, Podoltsev N, Barbarotta L, Hendrickson J, Gore S, Zeidan A. North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia Blood 2015, 126: 1138-1138. [DOI: 10.1182/blood.v126.23.1138.1138](https://doi.org/10.1182/blood.v126.23.1138.1138). [Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)](https://doi.org/10.1182/blood.v126.23.873.873)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United [DOI: 10.1182/blood.v126.23.873.873](https://doi.org/10.1182/blood.v126.23.873.873). [Myelodysplastic Syndromes and Acute after Radiotherapy, a Population-Based Study](https://doi.org/10.1182/blood.v126.23.3295.3295)Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Cancer after Radiotherapy: A Population-Based Study](https://doi.org/10.1182/blood.v126.23.1676.1676)Zeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: Population-Based Study Blood 2015, 126: Care from a Large National Database](https://doi.org/10.1182/blood.v126.23.3287.3287)Fletcher S, Cronin A, Zeidan A, Odejide O, Gore S, Davidoff A, Steensma D, Abel G. Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National Database Checkpoint Inhibitor Ipilimumab: A Phase I Trial](https://doi.org/10.1182/blood.v126.23.1666.1666)Zeidan A, Zeidner J, Duffield A, Knaus H, Ferguson A, Sheldon K, DeZern A, Gojo I, Gore S, Streicher H, Luznik L, of Myelodysplastic Syndromes (MDS) Following Agent (HMAs) Failure Using the Immune Checkpoint Inhibitor Ipilimumab: I Trial Blood 2015, 126: 1666-1666. 10.1182/blood.v126.23.1666.1666](https://doi.org/10.1182/blood.v126.23.1666.1666). [Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)](https://doi.org/10.1182/blood.v126.23.2889.2889)DeZern A, Zeidan A, Barnard J, Hand W, Al Ali N, Brown F, Zimmerman C, Roboz G, Komrokji R, Garcia-Manero G, Steensma D, Sekeres M. Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research (MDS CRC) Blood 2015, 126: 2889-2889. [DOI: 10.1182/blood.v126.23.2889.2889](https://doi.org/10.1182/blood.v126.23.2889.2889). [Results Phase 2 Trial Lenalidomide Monotherapy in Patients with Relapsed/Refractory Smith B, Carraway H, Gojo I, Sakoian S, Gore S, DeZern A. Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory clinical evaluating real-life effectiveness of exisiting therapies](https://doi.org/10.2217/ijh.15.25)Zeidan A. Myelodysplastic syndromes: from conductiong clinical trials of novel therapies to evaluating real-life effectiveness of exisiting therapies International Journal Of Hematologic Oncology 4: 215-217. [DOI: 10.2217/ijh.15.25](https://doi.org/10.2217/ijh.15.25). [Azacitidine for the of therapyrelated myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study](http://www.ncbi.nlm.nih.gov/pubmed/26577691)Prebet T, Sun Z, Ketterling RP, Zeidan A, Greenberg P, Herman J, Juckett M, Smith MR, Malick L, Paietta E, Czader M, Gabrilove J, Erba HP, Tallman MS, Litzow M, Gore SD, intergroup T. Azacitidine with or without Entinostat for the treatment of therapyrelated myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study British Journal Hensen M, Skikne B, Smith BD. Economic burden associated with acute myeloid leukemia treatment Expert patients with lowerrisk myelodysplastic syndromes: Is one model better?](http://www.ncbi.nlm.nih.gov/pubmed/26284571)Zeidan AM, Sekeres X, Ali N, GarciaManero G, Steensma DP, Roboz G, Barnard A, Maciejewski JP, List AF, Komrokji RS, Consortium O. Comparing the prognostic value of risk stratifying models for patients with lowerrisk myelodysplastic syndromes: Is one of patients with higher-risk myelodysplastic syndromes treated Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine](http://www.ncbi.nlm.nih.gov/pubmed/26440749)Zeidan AM, Ali N, Padron E, Lancet J, List A, Komrokji RS. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine Clinical Lymphoma patients with myelodysplastic syndromes (MDS)](https://doi.org/10.1016/j.clml.2015.07.094)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes N, Zeidan AM. The clinical use of DNA methyltransferase inhibitors in myelodysplastic syndromes Expert Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better?](http://www.ncbi.nlm.nih.gov/pubmed/26260295)Zeidan AM, Sekeres Al Ali N, Garcia-Manero Steensma Roboz G, JP, List AF, Komrokji RS. Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one North American Web-Based Survey](http://www.ncbi.nlm.nih.gov/pubmed/26363982)Lee EJ, Smith Merrey T, Luger AM. of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey Clinical OR, Subtil A. Leukaemic [DOI: 10.1016/s0140-6736(15)61165-5](https://doi.org/10.1016/s0140-6736(15)61165-5). [Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes](http://www.ncbi.nlm.nih.gov/pubmed/26274794)Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes Journal Of Comparative Effectiveness Patients with LowerRisk Myelodysplastic Syndromes: Is one model better?](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751065)Zeidan A, Sekeres M, Wang X, Ali N, GarciaManero G, Steensma D, Roboz G, Barnard J, Padron E, Dezern A, Maciejewski J, List A, Komrokji R. Comparing the Prognostic Value of Risk stratifying Models for Patients with LowerRisk Myelodysplastic Syndromes: Is one Oncologist: Will the Progress Fulfill the Promise?](http://www.ncbi.nlm.nih.gov/pubmed/26194858)Nazha A, Sekeres MA, Gore SD, Zeidan AM. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress MDS: Recent developments and future directions](http://www.ncbi.nlm.nih.gov/pubmed/26119927)Lee EJ, Podoltsev N, Gore SD, Zeidan AM. The evolving field of prognostication and risk stratification in MDS: Recent developments and future Blood Reviews 30: 1-10. [PMID: 26119927](https://pubmed.ncbi.nlm.nih.gov/26119927), Epigenetic Therapy in Acute Myeloid Leukemia: Current and A POPULATION-BASED STUDY](https://doi.org/10.1016/s0145-2126(15)30081-3)Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A Research BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM](https://doi.org/10.1016/s0145-2126(15)30321-0)Komrokii R, Zeidan A, Ali N, Padron E, Lancet J, Steensma D, Dezern A, Roboz G, Jabbour E, Sekeres M, RISK STRATIFICATION OF THERAPY-RELATED MYELODYSPLASTIC SYNDROMES (T-MDS): A REPORT ON BEHALF OF THE MDS CLINICAL RESEARCH CONSORTIUM Leukemia Research 2015, 39: s158-s159. [DOI: 10.1016/s0145-2126(15)30321-0](https://doi.org/10.1016/s0145-2126(15)30321-0). [44 DISEASE-SPECIFIC COSTS PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)](https://doi.org/10.1016/s0145-2126(15)30045-x)Zeidan A, Wang R, Davidoff A, Gore S, Gross C, Ma X. 44 DISEASE-SPECIFIC COSTS OF CARE AND SURVIVAL AMONG MEDICARE-ENROLLED PATIENTS WITH response](http://www.ncbi.nlm.nih.gov/pubmed/25869077)Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, Gore SD, Davidoff AJ. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer](http://www.ncbi.nlm.nih.gov/pubmed/25874142)Khan M, Wasim A, Mirrakhimov AE, McMahon BA, Judge DP, Chu LC, Banavali A, Zeidan AM. Case Report of a Patient with Left Ventricular Assistance Device Undergoing Chemotherapy for a New Diagnosis of Lung Cancer Case Reports In Oncological Komrokji RS. Current state of prognostication and risk stratification in benefit Baer MR, Stuart BC, Shenolikar RA, Gore SD. Patient Cost Sharing and Receipt of Erythropoiesis-Stimulating Agents Through Medicare Part D Parker, Oscar Colegio, Antonio Subtil. Leukaemic vasculitis from myelodysplastic syndrome. Lancet Journal. 2015 AM, Pronovost PJ, Haut ER. Eliminating Health Care Disparities With Mandatory Clinical Decision Support Medical Care the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)](https://doi.org/10.1182/blood.v124.21.1935.1935)Zeidan A, Sekeres M, Garcia-Manero G, Barnard J, Al Ali N, Zimmerman C, Roboz G, Steensma D, DeZern A, Jabbour E, Kantarjian H, Zell K, Wang Q, Gore S, Nazha A, Maciejewski J, List A, Komrokji R. The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated A, Zeidan AM. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes Journal Of Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy](http://www.ncbi.nlm.nih.gov/pubmed/25499624)Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-Life Experience of a Brief Arsenic Trioxide-Based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia: Favorable Outcomes With Limited Anthracycline Exposure and Shorter Consolidation Therapy Clinical Lymphoma Zeidan A. Hepatocellular carcinoma: systemic therapies and future perspectives Expert and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies](http://www.ncbi.nlm.nih.gov/pubmed/25072931)Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS](http://www.ncbi.nlm.nih.gov/pubmed/24995683)Zeidan AM, Lee J, Prebet T, Greenberg P, Sun Z, Juckett M, Smith MR, Paietta E, Gabrilove J, Erba HP, Katterling RP, Tallman MS, Gore SD. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS British hypomethylating agents failure in patients with myelodysplastic Zeidan A. An update on type 2B von Willebrand disease [DOI: 10.1586/17474086.2014.868771](https://doi.org/10.1586/17474086.2014.868771). - Amer M Zeidan Steven D. Gore. New Strategies in Acute Promyelocytic Leukemia: Moving to an Entirely Oral Chemotherapy-Free Upfront Management. Clinical Cancer Research Journal. 2014 Oct 1;20(19):4985-93. - Amer and Amy DeZern. Spontaneous Splenic rupture during induction therapy for acute myeloid leukemia. Leukemia and Lymphoma. 2014 Jan;55(1):209-12. - Mikhail S, Zeidan A. Stem cells in gastrointestinal cancers: The road less travelled. World Journal Of Related HLA-Haploidentical Bone Marrow Transplantation](http://www.ncbi.nlm.nih.gov/pubmed/24296490)Zeidan AM, Forde Symons H, Chen Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation Transplantation Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study](https://doi.org/10.1182/blood.v122.21.2777.2777)Prebet T, Sun Z, Ketterling R, Greenberg P, Zeidan A, Litzow M, Gabrilove J, Erba H, Paietta E, Czader M, Gore S, Tallman M. Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Intergroup Study Blood 2013, 122: 10.1182/blood.v122.21.2777.2777](https://doi.org/10.1182/blood.v122.21.2777.2777). [Validation Of a Brief Arsenic Trioxide Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival](https://doi.org/10.1182/blood.v122.21.3963.3963)Leech M, Stewart M, Zhang X, Bashey A, Holland H, Solomon S, Carraway H, Smith B, Morris L, Gore S, Zeidan A. Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent Survival Blood 2013, 122: 3963-3963. [DOI: 10.1182/blood.v122.21.3963.3963](https://doi.org/10.1182/blood.v122.21.3963.3963). [The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azactidine (aza)](https://doi.org/10.1182/blood.v122.21.2771.2771)Zeidan A, Ali N, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette P, Lancet J, List A, Komrokji R. The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) After Related T-Cell Posttransplantation Cyclophosphamide (PTCy)](https://doi.org/10.1182/blood.v122.21.4629.4629)Zeidan A, Forde P, Symons H, Chen A, Smith B, Fuchs E, Luznik L, Jones R, Bola\u00f1os-Meade J. The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell an international web-based survey of healthcare providers](http://www.ncbi.nlm.nih.gov/pubmed/24092259)Zeidan AM, Wellman Forde J, Streiff thromboembolism stem cell transplantation patients: an international web-based survey of healthcare providers Journal Boikos S, Bose S, Lipsett P, D, King KE, Gerber J, DeZern A. Spontaneous splenic rupture during induction chemotherapy for acute prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza).](https://doi.org/10.1200/jco.2013.31.15_suppl.7126)Zeidan A, Sun Z, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. Application of the French prognostic score (FPS) to assess overall survival (OS) in a U.S.-based cohort of patients (pts) treated with azacitidine (Aza). Journal Of Clinical Oncology 2013, 31: 7126-7126. [DOI: 10.1200/jco.2013.31.15_suppl.7126](https://doi.org/10.1200/jco.2013.31.15_suppl.7126). [Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload (TIO).](https://doi.org/10.1200/jco.2013.31.15_suppl.e17584)Gore S, Davidoff Hendrick F, Duong V, Stuart B, Baer M, Shenolikar R, Zeidan A. Effect of availability of oral iron chelation therapy (ICT) on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes (MDS) and transfusional iron overload 2013, 31: e17584-e17584. [DOI: 10.1200/jco.2013.31.15_suppl.e17584](https://doi.org/10.1200/jco.2013.31.15_suppl.e17584). - Zeidan A, Myelodysplastic Syndrome 2013, 189-210. [DOI: 10.1007/978-3-642-36229-3_12](https://doi.org/10.1007/978-3-642-36229-3_12). [P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine](https://doi.org/10.1016/s0145-2126(13)70172-3)Zeidan A, Zhuoxin S, Prebet T, Greenberg P, Juckett M, Smith M, Paietta E, Gabrilove J, Erba H, Gore S, Tallman M. P-124 Application of the French Prognostic Score to assess overall survival in a US-based cohort of patients treated with azacitidine Leukemia Research 2013, 37: s79-s80. [DOI: 10.1016/s0145-2126(13)70172-3](https://doi.org/10.1016/s0145-2126(13)70172-3). [P-181 Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes](https://doi.org/10.1016/s0145-2126(13)70229-7)Zeidan A, Davidoff A, Hendrick F, Duong V, Stuart B, Baer M, Gore S. P-181 Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes Leukemia Research 2013, 37: performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes](https://doi.org/10.1016/s0145-2126(13)70207-8)Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. P-159 Lenalidomide performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes Leukemia Research 2013, 37: azacitidine-lenalidomide Zeidan, Steven Gore, Rami Komrokji - Iron Chelation for Myelodysplastic Syndromes-associated Iron Overload: Where Do we Stand?Mhairi Mitchell, Steven Gore, and Amer Zeidan - Myelodysplastic Syndromes: Jocelyn Wozney, Karen Krok, and Javier Bola\u00f1os-Meade. Successful Treatment of severe refractory hepatic graft versus host disease by cadaveric liver transplantation. Leukemia and Lymphoma. 2013 Dec;54(12):2756-9. - What lies within - Novel Strategies in Immunotherapy for Non-Small-Cell Lung CancerPatrick M. Forde, Kim A. Reiss, Amer M. Zeidan, and Julie Brahmer - Sustained Complete Cytogenetic Remission in a Patient with Myelodysplastic Syndrome and Complex Karyotype after Ronald Sham - Adult Primary Pulmonary Primitive Neuroectodermal Tumor: molecular features and translational opportunitiesMirela Andrei, Stewart Cramer, Kramer, Amer Zeidan, and Faltas - Amer Zeidan, Patrick Forde, and Streiff. Diagnosis, Treatment, and Prevention of Cancer-Related Venous Thrombosis. The 35th chapter in Abeloff's Edited by Niederhuber, Armitage, Doroshow, Kastan, and Tepper. Elsevier. 2013. - Amer Zeidan and Steven Gore. Management of High-Risk Myelodysplastic Syndrome. A book chapter in Myelodysplastic Syndromes, 2nd Edition. Edited by H. Joachim Deeg. Springer. 2013. - Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock and 2013 PMID: 23844446. Review [Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey](https://doi.org/10.1182/blood.v120.21.2062.2062)Zeidan A, Forde P, Bolanos-Meade J, Streiff M. Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: A International Web-Based Survey Blood 2012, 2062-2062. [DOI: 10.1182/blood.v120.21.2062.2062](https://doi.org/10.1182/blood.v120.21.2062.2062). [Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.3837.3837)Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes Blood 2012, 120: 3837-3837. [DOI: 10.1182/blood.v120.21.3837.3837](https://doi.org/10.1182/blood.v120.21.3837.3837). [Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.426.426)Zeidan A, Hendrick F, Friedmann E, Gore S, Baer M, Sasane M, Paley C, McNally D, Davidoff A. Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes Blood 2012, 120: 426-426. [DOI: 10.1182/blood.v120.21.426.426](https://doi.org/10.1182/blood.v120.21.426.426). [Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes](https://doi.org/10.1182/blood.v120.21.971.971)Hendrick F, Davidoff A, Zeidan A, Gore S, Baer M. Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic Syndromes Blood 2012, 120: 971-971. [DOI: 10.1182/blood.v120.21.971.971](https://doi.org/10.1182/blood.v120.21.971.971). [Medicare Prescription and Agents for MDS-Associated Anemia: A Medicare-Database Analysis.](https://doi.org/10.1182/blood.v120.21.3176.3176)Davidoff A, Hendrick F, Stuart B, Zeidan A, Shenolikar R, Gore S, Baer M. Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: Iron Chelation Therapy Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.](https://doi.org/10.1182/blood.v120.21.3178.3178)Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178-3178. [DOI: 10.1182/blood.v120.21.3178.3178](https://doi.org/10.1182/blood.v120.21.3178.3178). - Zeidan A, Streiff P, Hobson D, Horn P, Shermock K, Tinoco G, E. Impact of a Venous Thromboembolism Prophylaxis \"Smart Orderset\": [DOI: 10.1182/blood.v118.21.172.172](https://doi.org/10.1182/blood.v118.21.172.172). [Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Leukemias,](https://doi.org/10.1182/blood.v118.21.3615.3615)Zeidan A, Carraway H, Yun H, Greer J, Karp J. Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute Biology in Normal and Malignant Hematopoiesis. A book chapter in Leukemias: Principles and Practice of Therapy. Edited by H. Kantarjian and S. Faderl. Blackwell. 2011. - Zeidan A, Wetzler M. Stemcell Biology 2010, Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).](https://doi.org/10.1182/blood.v112.11.952.952)Zeidan A, Tan W, Wilding G, Ford L, Hahn T, Smiley S, Battiwalla M, McCarthy P, Wang E, Wetzler M. Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior and Kevin McGrody. A case of primary meningococcal pericarditis caused by serotype Y Neisseria meningitides with rapid evolution into pericardial tamponade. Journal of General Internal Medicine, September 2008; 23(9):1532-1535. - Mediastinal mass in a patient with coronary artery disease. A medical image.Amer Zeidan [Frequent Molecular Aberrations in Normal Karyotype (NC) Leukemia Detected Genomic Hybridization.](https://doi.org/10.1182/blood.v110.11.4270.4270)Zeidan A, Gaile D, Conroy J, McQuaid D, Wang E, Deeb G, Wallace P, Sait S, Nowak N, Wetzler M. Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia 4270-4270. [DOI: 10.1182/blood.v110.11.4270.4270](https://doi.org/10.1182/blood.v110.11.4270.4270). - Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park Street, Ste NP-7New Haven, CT 06511 - Yale Cancer CenterSmilow Cancer Hospital at Yale New Haven35 Park "}